



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 39/395, C07K 16/28, C12N 1/38, G01N 33/53		A1	(11) International Publication Number: <b>WO 95/15180</b> (43) International Publication Date: 8 June 1995 (08.06.95)
(21) International Application Number: PCT/US94/13708		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 1 December 1994 (01.12.94)			
(30) Priority Data: 08/162,597 3 December 1993 (03.12.93) US			
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).		Published <i>With international search report.</i>	
(72) Inventors: CLARY, Douglas, O.; 233 Liberty Street, San Francisco, CA 94114 (US). WESKAMP, Gisela; Apartment 6B, 402 E. 64th Street, New York, NY 10021 (US). AUSTIN, Leann; 8231 Geary Boulevard, San Francisco, CA 94121 (US). REICHARDT, Louis, F.; 900 Darien Way, San Francisco, CA 94127 (US).			
(74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 North Figueroa Street, Los Angeles, CA 90012 (US).			

(54) Title: ANTIBODIES THAT MIMIC ACTIONS OF NEUROTROPHINS

(57) Abstract

The use and production of immunoglobulins which activate *trk* receptors and imitate effects of neurotrophins are provided. Immunoglobulins which block *trk* receptor activation and methods of use are also provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ANTIBODIES THAT MIMIC ACTIONS OF NEUROTROPHINS  
FIELD OF THE INVENTION

This invention relates to the use and production of immunoglobulins which activate *trk* 5 neurotrophin receptors.

This invention was made with Government support under Grant No. MH 28300, awarded by the National Institutes of Health. The Government has certain rights in this invention.

10

BACKGROUND OF THE INVENTION

The neurotrophins are a family of small, homodimeric proteins which promote effects on distinct but partially overlapping sets of neurons 15 (Levi-Montalcini, R., *Science* 237:1154-62 (1987); Barde, Y. A., *Neuron* 2:1525-1534 (1989); Korschning, S., *J. Neurosci.* 13:2739-2748 (1993); Eide, F. F., Lowenstein, D. H. and Reichardt, L. F., *Exp. Neurol.* 121:200-214 (1993). For instance, nerve growth 20 factor (NGF), a well characterized member of the neurotrophin family, functions as a target-derived molecule which aids in determining the level of innervation during development by regulating the survival and differentiation, including process 25 outgrowth, of the innervating neuronal population. NGF has effects on apoptosis (programmed cell death) and influences many facets of neuronal development; for example, regulation of axon branching and of gene expression (Barde, 1989).

30 In addition to NGF, some other members of the neurotrophin family include brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). These various growth factors show selectivity with some overlap as to 35 their responsive neurons in the peripheral nervous system (PNS) and central nervous system (CNS). For

instance, neurons responsive to NGF include sympathetic neurons and neural crest sensory neurons in the PNS and basal forebrain cholinergic neurons, striatal cholinergic neurons and cerebellar Purkinje 5 cells in the CNS. PNS neurons responsive to BDNF include placode-derived sensory neurons, neural crest sensory neurons, nodose ganglion neurons and spinal motoneurons. BDNF responsive neurons in the CNS include basal forebrain cholinergic neurons, 10 proprioceptive trigeminal neurons, substantia nigra dopaminergic neurons, retinal ganglion neurons and facial motoneurons. NT-3 responsive neurons include sympathetic and sensory neurons in the PNS and basal forebrain cholinergic neurons and locus coeruleus 15 neurons in the CNS. NT-4/5 responsive neurons in the PNS include sympathetic neurons, dorsal root ganglion neurons and nodose ganglion neurons. NT-4/5 CNS responsive neurons include basal forebrain cholinergic neurons and locus coeruleus neurons.

20 Redundancy of the neurotrophins and their receptors exists. For instance, *trkA* receptors bind the neurotrophins NGF, NT-3 and NT-4/5. The receptor *trkB* binds the neurotrophins BDNF, NT-3 and NT-4/5. The receptor *trkC* binds NT-3. Although 25 neurotrophins often recognize more than one receptor, they may activate different receptors to different degrees. For example, NT-3 activates *trkA* moderately, and *trkB* and *trkC* strongly.

Neurotrophins are of interest as potential 30 therapeutic agents for a variety of neurodegenerative and neurologic diseases. There are a number of disorders which may relate to suboptimal activity of *trk* receptors or which are associated with inappropriate activity or levels of 35 neurotrophins. These neurologic disorders include Alzheimer's Disease, Parkinson's Disease, amyotrophic

lateral sclerosis (ALS), cerebral ischemia, nerve tissue ischemia, peripheral neuropathy (especially toxic and diabetic peripheral neuropathies), nervous system cancer and epilepsy. Alzheimer's Disease, 5 Parkinson's Disease, ALS, the ischemias, and the neuropathies can be broadly be classified as neurodegenerative disorders.

Parkinson's Disease is also known as paralysis agitans and shaking palsy. It is a 10 chronic, progressive central nervous system disorder characterized by muscular rigidity, tremors and slow purposeful movement as well as a decrease in purposeful movement. Classical Parkinson's Disease is of unknown ideology. However, a Parkinson's 15 syndrome can be drug-induced or caused by poisonings, such as carbon monoxide poisoning, and also by infarction or death of cells in the vicinity of the basal ganglia. Such cell death can be caused by insufficient blood flow, tumors and head trauma. 20 Additionally, a postencephalitic Parkinsonism is known. Parkinson's Disease tends to have insidious onset and a slowly progressive course. It tends to become incapacitating after a number of years.

An additional group of neurogenic 25 disorders includes ALS which is an example of a neurogenic muscular atrophy. Other examples are infantile and juvenile spinal muscular atrophy which, like ALS, are anterior horn cell degenerative diseases. ALS is also know as Lou Gherrig's Disease 30 and includes progressive spinal-muscular atrophy and progressive bulbar palsy. In ALS, muscular weakness and atrophy typically begin in the hands and spread to the forearms and the legs. Muscles fasiculations progressing to spasticity, increased tendon reflexes 35 and extensor plantar reflexes are also characteristic. The afflicted individual generally

dies within several years, typically surviving no more than five years. Variants of ALS include progressive spinal-muscular atrophy or Aran-Duchenne muscular atrophy and progressive bulbar palsy or 5 Duchenne's paralysis or labioglossolaryngeal paralysis.

Peripheral neuropathies and peripheral neuritis include a large group of sensory, motor, reflex and vaso-motor symptoms which may be single 10 or in combination and which may be produced by disease of a single nerve (mononeuropathy), or two or more nerves in separate areas (mononeuritis multiplex), or many nerves simultaneously (polyneuropathy, polyneuritis, multiple peripheral 15 neuritis or multiple peripheral neuropathy). The etiologies include collagen vascular conditions, infections, toxic agents, malignancies, metabolic and autoimmune causes. For example, a toxic peripheral neuropathy can be caused by the 20 chemotherapeutic agent taxol which can disrupt axonal transport in peripheral neurons. This causes pain in the nerve distribution of the afflicted neurons. Diabetic neuropathy is another example of a peripheral neuropathy. In diabetic neuropathy, 25 peripheral sensory and sympathetic neurons tend to be affected early in the course of the disease usually causing pain or decreased sensation.

Epilepsy or seizure disorder includes a variety of seizures characterized by recurrent 30 paroxysmal cerebral dysfunction associated with sudden, usually brief, attacks of altered consciousness, motor activity, sensory phenomena or inappropriate behavior. Any recurrent seizure pattern can be called epilepsy. Convulsive seizures 35 are probably the most common form of attack and they begin with loss of consciousness and loss of motor

control followed by tonic or clonic jerking of the extremities. In about three quarters of seizure cases in adults, no clear etiology is identified and the seizure is termed "symptomatic" or "idiopathic."

5 Some of the known causes of seizures include cerebral trauma, tumors or other brain disease, CNS infections, hyperpyrexia such as that associated with acute infection or heat stroke, toxic agents, metabolic disturbances, cerebral infarction or

10 hemorrhage, cerebral hypoxia and a variety of other causes. Drug therapy with anticonvulsive agents is frequently effective.

There has been some exploration of the possibility of using neurotrophins to treat disease.

15 For example, in animal models of both taxol toxic and diabetic peripheral neuropathies, NGF was used as a therapy with varying degrees of success. See Eide, et al. at page 206. However, because of the redundancy of neurotrophin-receptor recognition and

20 because of variability in the strength of activation of their corresponding receptors, neurotrophins present complex problems as potential therapeutic agents. Additionally, several physiologic mechanisms exist for rapidly clearing neurotrophins

25 from the circulation, including the presence of receptor-like binding proteins whose main function may be to sequester the neurotrophins. Additionally neurotrophins are difficult to prepare in quantity because of complex requirements for post-

30 translational processing and their lability to proteases.

The importance of the neurotrophins has stimulated interest in their receptors and signal transduction mechanisms. Most approaches have focused on the pheochromocytoma cell line PC12, which is transformed into a sympathetic neuron-like

cell when exposed to NGF (Greene, L. A. and Tischler, A., *Proc. Natl. Acad. Sci. USA* 73:2424-2428 (1976)). NGF binding studies indicated that NGF could bind to at least two different sites, a 5 low affinity or fast-dissociating binding site, and a high affinity or slow-dissociating binding site (Sutter, et al., *J. Biol. Chem.* 254:5972-5982 (1979); Schechter, A. L. and Bothwell, M. A., *Cell.*, 24, 867-874 (1981)).

10 A receptor for NGF, known as the low affinity nerve growth factor receptor (LNGFR), has been cloned from rat and human sources (Radeke, et al., 325:593-7 (1987); Johnson, et al., *Cell.* 47:545-554 (1986)). It is a transmembrane 15 glycoprotein of 75,000 daltons, and it is expressed in many neuronal and nonneuronal cell types (Wyatt, et al., *Neuron.* 4:421-7 (1990); Wheeler, E. F. and Bothwell, M., *J. Neurosci.* 12:930-45 (1992)). However, LNGFR was unable to bind NGF with a high 20 affinity in transfected fibroblastic cell lines (Radeke, et al., 1987).

Crosslinking studies (Hosang, M. and Shooter, E. M., *J. Biol. Chem.* 260:655-662 (1985)), biochemical characterization (Meakin, S. O. and 25 Shooter, E. M., *Neuron.* 6:153-163 (1991); Radeke, M. J. and Feinstein, S. C., *Neuron.* 7:141-50 (1991)), and binding and culture studies with the anti-LNGFR polyclonal antibody REX (Weskamp, G. and Reichardt, L. F., *Neuron.* 6:649-63 (1991)) implied that another 30 receptor for NGF is expressed by PC12 cells. That receptor has since been identified as the receptor tyrosine kinase p140<sup>trk</sup> or trkA (Kaplan, et al., *Science.* 252:554-8 (1991); Klein, et al., *Cell.* 65:189-97 (1991)).

TrkA is expressed in sensory and sympathetic neurons in the peripheral nervous system, and basal forebrain neurons in the central nervous system, all cell types which show responses to NGF (Martin-Zanca, et al., *Genes Dev.* 4:683-94 (1990); Schecterson, L. C. and Bothwell, M., *Neuron*. 9:449-63 (1992); Holtzman, et al., *Neuron*. 9:465-78 (1992)). Biochemical studies have demonstrated that trkA is phosphorylated in response to NGF (Kaplan, et al., *Nature* 350:158-60 (1991); Klein, et al., (1991); Jing, et al., *Neuron*. 9:1067-79 (1992)), and subsequently trkA activates several signal transduction pathways (Vetter, et al., *Proc. Natl. Acad. Sci. USA* 88:5650-4 (1991); Loeb, et al., *Neuron*. 9:1053-65 (1992); Obermeier, et al., *Embo. J.* 12:933-941 (1993)).

TrkB and trkC, two receptors closely related to trkA, have been isolated and can respond to other members of the neurotrophin family (Martin-Zanca, et al., *Mol. Cell. Biol.* 9:24-33 (1989); Klein, R., et al., *Embo. J.* 8:3701-9 (1989); Middlemas, et al., *Mol. Cell. Biol.* 11:143-53 (1991); Lamballe, et al., (1991)).

25

#### SUMMARY OF THE INVENTION

The invention relates to the discovery that selected immunoglobulins can activate trk receptors and mimic the actions of neurotrophins. Included in the invention are methods for activating a trk receptor comprising exposing cells having the trk receptor to a multivalent immunoglobulin which binds to the receptor and activates the receptor. The trk receptor is any of a number of tyrosine kinase receptors, and preferably it is any of trkA, 30 trkB, and trkC.

Activation of the receptor can be noted by a variety of means including increased phosphorylation of the receptor, increased phosphorylation of protein substrates that are 5 phosphorylated in response to activation of the receptor, and promotion of the effector function or outcome of receptor activation. Examples of such functions or outcomes include promotion of neuronal survival and promotion of neuronal differentiation 10 including neurite outgrowth.

The multivalent immunoglobulin is preferably bivalent, although it can be polyvalent. Typically the immunoglobulin is a monoclonal antibody.

15 The invention includes methods of therapy for neurologic disorders associated with suboptimal activity of a *trk* receptor. Such disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cerebral 20 ischemia, nerve tissue ischemia, peripheral neuropathy, particularly toxic and diabetic peripheral neuropathy, nervous system cancer, and epilepsy. Examples of nervous system cancer are primitive neuroectodermal tumors, neuroblastomas, 25 medulloblastomas, ganglioneuromas, Ewing's sarcoma, gliomas, glioblastomas, and astrocytomas.

The therapeutic method includes administering to a mammal having the disorder a therapeutically effective amount of a multivalent 30 immunoglobulin of the invention. Usually the mammal is a human, although veterinary use is also contemplated. The administration is preferably parenteral, especially intraventricular, intravenous or intramuscular. The effective amount is an amount 35 sufficient to cause a desired effect such as a therapeutic benefit. Typically, the dosage is

selected from the range of from about 1  $\mu$ g/kg to about 1 mg/kg body weight of the recipient mammal for a polyclonal antibody. The range for a monoclonal antibody is usually about 5% to about 10% 5 of the polyclonal antibody range.

A method for diagnosing a neurologic disorder associated with suboptimal activity of a trk receptor is also supplied. The method includes obtaining a nerve cellular sample, exposing the 10 sample to a multivalent immunoglobulin which (1) binds to the receptor and (2) activates the receptor, and assaying the sample for (1) binding to the immunoglobulin and (2) activation of the receptor.

15 Also provided is a method for determining whether cellular material has a trk receptor. This method includes exposing the cellular material to a multivalent immunoglobulin which both binds to and activates the receptor and assaying the cellular 20 material for binding to the immunoglobulin and activation of the receptor.

Thus, the invention provides immunoglobulins that mimic the actions of neurotrophins. Appropriately designed 25 immunoglobulins able to dimerize the neurotrophin-receptors can activate these receptors and serve as neuronal survival and differentiation-promoting agents. Such immunoglobulins are easier to prepare, are more stable, and are likely to be longer acting 30 than neurotrophins. In some cases immunoglobulins can be designed to act with greater selectivity than certain neurotrophins, several of which recognize more than one receptor. Bifunctional organic molecules that bind neurotrophin receptors are 35 likely to also activate these receptors.

5 Immunoglobulins able to bind and cross-link the trk family of neurotrophin-receptors are shown herein to activate these receptors and produce consequences in neurons indistinguishable from 10 exposure to a neurotrophin. Bivalent or polyvalent antibodies or immunoglobulins are required. Observed activation sequelae include tyrosine phosphorylation of the trk-receptor, tyrosine phosphorylation of the protein substrates that are 15 phosphorylated as a response to the neurotrophin, promotion of neuronal survival, and promotion of neuronal differentiation including neurite outgrowth. Thus, the immunoglobulins mimic the actions of the neurotrophins.

15 Also provided are immunoglobulins, and methods of use, which are monovalent and which bind to and prevent activation of trk receptors. Such immunoglobulins and methods block the relevant receptor and prevent the receptor's effect or 20 function from occurring.

25 Immunoglobulins can be designed to recognize only single receptors. Included herein are data supporting detection of differentially spliced exons encoding extracellular domains in trk. Immunoglobulins recognizing specific receptor isoforms can be prepared. Immunoglobulins have different, and in some cases more restricted, specificities that are useful for targeting the therapy.

30 Immunoglobulins, especially monoclonal antibodies, are easy to prepare and purify. They can be designed to eliminate problems of antigenic responses or complement activation. They have considerable therapeutic potential in general. 35 Additionally, they may be more efficiently delivered to neurons than are neurotrophins. Immunoglobulins

would not be cleared as rapidly by their respective receptors and they are comparatively easy to prepare and purify. Also they are resistant to most proteases.

5

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1A is a dose response graph of a whole cell binding assay with antibodies of the invention.

10

Fig. 1B is a whole-cell binding bar graph showing the additive effects of an antibody of the invention and another antibody.

Fig. 2 is an analysis of NGF binding cites resistant to two antibodies of the invention.

15

Fig. 3 is a graph of neuron survival after treatment with antibody fragments of the invention.

Fig. 4 is a bar graph showing promotion of neuron survival by an antibody of the invention.

20

#### DETAILED DESCRIPTION

This invention provides immunoglobulin peptides which bind to and activate trk receptors and methods of use. Additionally, monovalent immunoglobulin peptides which bind to and block activation of trk receptors and methods of use are provided.

The term "tyrosine kinase" refers to a family of enzymes which possess in common the ability to phosphorylate (add a phosphate group to) the amino acid tyrosine. The tyrosine kinases are tightly regulated in animal cells. One fairly well characterized tyrosine kinase is epidermal growth factor receptor which assists in initiating cell division by phosphorylating key proteins. For information about the protein kinase families and hallmarks of each family, see generally Hanks, et

al. *Science* 241:42-52 (1988), incorporated by reference herein.

The neurotrophins bind to appropriate tyrosine kinase receptors. Several features are 5 considered hallmarks of the *trk* tyrosine kinase receptor family. For example, see Klein, et al. *EMBO* 8(12) 3701-3709 (1989) and Schneider, R. and M. Schweiger, *Oncogene* 6:1807-1811 (1991), both of which are incorporated by reference herein. 10 Specifically, four features unique to the *trk* receptor family have been identified and include (1) a single amino acid gap between residues 575 and 576 in mouse *trkB*, residues 542 and 543 in human *trkA*; (2) a threonine in position 678 in mouse *trkB*, 15 position 647 in human *trkA*; (3) a tryptophan in position 753 in *trkB*, position 722 in human *trkA*; and (4) the absence of the helix-breaking proline in position 797 in *trkB*, position 766 in human *trkA*.

Relating to preferred embodiments, three 20 closely related tyrosine kinase receptors are known currently: *trkA*, *trkB* and *trkC*. The *trk* receptor proteins include an extracellular domain for ligand recognition, a single transmembrane domain and a cytoplasmic tail which contains the tyrosine kinase. 25 The cytoplasmic tail initiates the signalling cascade. The extracellular domain has two immunoglobulin-like domains that bind neurotrophins. The actual process or mechanism of activation is not clear, but it is thought that the receptors are 30 activated by allosteric dimerization such that the tyrosine kinase receptors form oligomers in response to binding by an appropriate growth factor. The receptor identified as the receptor tyrosine kinase *p140<sup>trk</sup>* or *trkA* is described in Kaplan, et al., *Science* 252:554-8 (1991) and Klein, et al., *Cell*. 35

65:189-97 (1991), both incorporated by reference herein.

TrkA is expressed in sensory and sympathetic neurons in the peripheral nervous system, and basal forebrain neurons in the central nervous system, all cell types which show responses to NGF (Martin-Zanca, et al., *Genes Dev.* 4:683-94 (1990); Schecterson, L. C. and Bothwell, M., *Neuron.* 9:449-63 (1992); Holtzman, et al., *Neuron.* 9:465-78 (1992), all incorporated by reference herein). Biochemical studies have demonstrated that trkA is phosphorylated in response to NGF (Kaplan, et al., *Nature* 350:158-60 (1991); Klein, et al., (1991); Jing, et al., *Neuron.* 9:1067-79 (1992), all incorporated by reference herein), and subsequently trkA activates several signal transduction pathways (Vetter, et al., *Proc. Natl. Acad. Sci. USA* 88:5650-4 (1991); Loeb, et al., *Neuron.* 9:1053-65 (1992); Obermeier, et al., *Embo. J.* 12:933-941 (1993), all incorporated by reference herein).

TrkB and trkC, two receptors closely related to trkA, have been isolated and can respond to other members of the neurotrophin family (Martin-Zanca, et al., *Mol. Cell. Biol.* 9:24-33 (1989); Klein, R., et al., *Embo. J.* 8:3701-9 (1989); Middlemas, et al., *Mol. Cell. Biol.* 11:143-53 (1991); Lamballe, et al., (1991), all incorporated by reference herein).

Immunoglobulins or antibodies are typically composed of four covalently bound peptide chains. For example, an IgG antibody has two light chains and two heavy chains. Each light chain is covalently bound to a heavy chain. In turn each heavy chain is covalently linked to the other to form a "Y" configuration, also known as an immunoglobulin conformation. Fragments of these

molecules, or even heavy or light chains alone, may bind antigen. Antibodies, fragments of antibodies, and individual chains are also referred to herein as immunoglobulins.

5 A normal antibody heavy or light chain has an N-terminal (NH<sub>2</sub>) variable (V) region, and a C-terminal (-COOH) constant (C) region. The heavy chain variable region is referred to as V<sub>H</sub> (including, for example, V<sub>Y</sub>), and the light chain 10 variable region is referred to as V<sub>L</sub> (including V<sub>S</sub> or V<sub>λ</sub>). The variable region is the part of the molecule that binds to the antibody's cognate antigen, while the Fc region (the second and third domains of the C region) determines the antibody's 15 effector function (e.g., complement fixation, opsonization).

An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, also 20 called complementarity-determining regions or CDRs. The extent of the framework region and CDRs have been defined (see, "Sequences of Proteins of Immunological Interest," E. Kabat, et al., U.S. Department of Health and Human Services, (1987); 25 which is incorporated herein by reference). The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of 30 the constituent light and heavy chains, serves to position and align the CDRs in three dimensional space. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs are typically referred to as CDR1, CDR2, and CDR3, 35 numbered sequentially starting from the N-terminus.

The two types of light chains,  $\kappa$  and  $\lambda$ , are referred to as isotypes. Isotypic determinants typically reside in the constant region of the light chain, also referred to as the  $C_L$  in general, and  $C_{\kappa}$  or  $C_{\lambda}$  in particular. Likewise, the constant region of the heavy chain molecule, also known as  $C_H$ , determines the isotype of the antibody. Antibodies are referred to as IgM, IgD, IgG, IgA, and IgE depending on the heavy chain isotype. The isotypes are encoded in the mu ( $\mu$ ), delta ( $\Delta$ ), gamma ( $\gamma$ ), alpha ( $\alpha$ ), and epsilon ( $\epsilon$ ) segments of the heavy chain constant region, respectively. In addition, there are a number of  $\gamma$  subtypes.

15 Immunoglobulins are frequently classified according to their valency. IgG is a bivalent antibody and IgM is a polyvalent antibody. The valency refers to the number of binding sites on the immunoglobulin. As used herein, the term multivalent means that one antibody molecule binds 20 two or more receptors. Bivalent means that the antibody binds to two receptors and polyvalent means that it binds to more than two receptors. Polyclonal antibodies generally comprise a mixture 25 of bivalent antibodies. Methods of the invention relating to activation of a *trk* receptor include the use of bivalent and polyvalent immunoglobulins (that is, multivalent but not monovalent immunoglobulins). In preferred embodiments a single bivalent monoclonal antibody or a mixture of bivalent 30 antibodies, such as monoclonal antibodies, is used. More preferably, the immunoglobulins can include a mixture of at least two monoclonal antibodies.

35 The heavy chain isotypes determine different effector functions of the antibody. In addition, the heavy chain isotype determines the secreted form of the antibody. Secreted IgG, IgD,

and IgE isotypes are typically found in single unit or monomeric form. Secreted IgM isotype is found in pentameric form; secreted IgA can be found in both monomeric and dimeric form.

5       Mouse monoclonal antibodies have been described against the extracellular portion of *trk*. See, for example, Eager, K., *Onc.* 6(5):819-824 (May 1991) and EPA No. 91112109 (Pub. No. 0471205A1).

10      Murine, human, chimeric or other immunoglobulins, especially those of mammalian origin, may be used with the invention. The immunoglobulins can be prepared in a variety of ways known in the art, depending upon whether monoclonal or polyclonal antibodies are desired. For 15 polyclonal antibodies, a vertebrate, typically a domestic animal, is hyperimmunized with the antigen, blood from the vertebrate is collected shortly after immunization and the gamma globulin is isolated. Suitable methods for preparing polyclonal antibodies 20 are described in the *Handbook of Experimental Immunology*, 3d ed., Weir (ed.), Blackwell Scientific Publications (1978).

For monoclonal antibodies, a small animal, typically a rat or mouse, is hyperimmunized with 25 antigen, the spleen is removed and the lymphocytes are fused with myeloma cells in the presence of a suitable fusion promoter. The resulting hybrid cells or hybridomas are screened to isolate 30 individual clones, each of which secrete a single antibody species to the antigen. The individual antibody species are each the product of a single B cell generated in response to a specific antigenic site recognized on the antigen or immunogenic substance. The process for obtaining monoclonal 35 antibodies is described by Kohler and Milstein, *Nature*, 256:495 (1975). See also Harlow and Lane,

*Antibodies: A Laboratory Manual*, Cold Spring Harbor Publications, N.Y. (1988). The peptides or antigens used to generate the antibodies, depending upon their own immunogenicity, may be used directly in 5 the immunization procedure as immunogenic components associated with living or fixed cells or they may be bound to a suitable carrier protein, such as keyhole limpet hemocyanin (KLH), human or bovine serum albumin (HSA or BSA), and the like. Use of the 10 antigen with a carrier protein is preferred.

The DNA sequences associated with this invention comprise DNA subsequences encoding amino acid sequences of the antibody heavy or light chains, or fragments thereof, which determine 15 binding specificity for a *trk* receptor protein such as those derived from *trkA*. These sequences may be ligated, for example, into human constant region expression vectors, and inserted into a host cell. The host cell can then express a recombinant 20 chimeric or hybrid antibody that is specific for binding to a *trk* receptor protein or polypeptide.

"Immunoglobulin" or "antibody peptide(s)" refers to an entire immunoglobulin or antibody or any functional fragment of an immunoglobulin 25 molecule. Examples of such peptides include complete antibody molecules, antibody fragments, such as Fab, F(ab')<sub>2</sub>, CDRs, V<sub>L</sub>, V<sub>H</sub>, and any other portion of an antibody. As described above, an IgG antibody molecule is composed of two light chains 30 linked by disulfide bonds to two heavy chains. The two heavy chains are, in turn, linked to one another by disulfide bonds in an area known as the hinge region of the antibody. A single IgG molecule typically has a molecular weight of approximately 35 150-160 kD and containing two antigen binding sites.

An F(ab')<sub>2</sub> fragment lacks the C-terminal portion of the heavy chain constant region, and has a molecular weight of approximately 110 kD. It retains the two antigen binding sites and the 5 interchain disulfide bonds in the hinge region, but it does not have the effector functions of an intact IgG molecule. An F(ab')<sub>2</sub> fragment may be obtained from an IgG molecule by proteolytic digestion with pepsin at pH 3.0-3.5 using standard methods such as 10 those described in Harlow and Lane, *supra*.

The use of high concentrations of mouse antibodies (or other nonhuman antibodies) in humans has certain limitations. There are instances of anti-framework or anti-idiotype antibodies 15 generation over the course of longterm therapy. Therefore, chimeric antibodies may also be used in the combination of this invention, which can minimize an antimurine response. Chimeric antibodies are usually combinations of portions of 20 human and murine antibodies with the variable region of the murine line combined with the invariant or constant region of the human line. An example of a successful human/murine chimeric antibody is one for carcinoembryonic (CEA) antigen described by Beidler, 25 et al., *J. of Immunology*, 141:4053 (1988). Other methods for constructing chimeric antibodies and binding fragments are described in Brown et al., *Cancer Research* 47:3577-3583 (1987); Kameyama et al., *FEB* 2:301-306 (1989); Orlandi et al., *Proc. 30 Nat'l Acad. Sci. USA* 86:3833-3837 (1989); Beidler et al., *J. Immun.* 141:4053 (1986); Sahagan et al., *J. Immunol.* 3:1066 (1986); Bird et al., *Science* 242:123 (1988); Morrison et al., *Clin. Chem.* 34:1668-1675 (1988); Better et al., *Science* 240:1041 (1988) and 35 Morrison and Oi, *Advances in Immunology* 44:55 (1989) all of which are incorporated by reference herein.

"Chimeric antibodies" or "chimeric peptides" refer to those antibodies or antibody peptides wherein one portion of the peptide has an amino acid sequence that is derived from, or is 5 homologous to, a corresponding sequence in an antibody or peptide derived from a first gene source, while the remaining segment of the chain(s) is homologous to corresponding sequences of another gene source. For example, a chimeric antibody 10 peptide may comprise an antibody heavy chain with a murine variable region and a human constant region. The two gene sources will typically involve two species, but will occasionally involve one species.

Chimeric antibodies or peptides are 15 typically produced using recombinant molecular and/or cellular techniques. Typically, chimeric antibodies have variable regions of both light and heavy chains that mimic the variable regions of antibodies derived from one mammalian species, while 20 the constant portions are homologous to the sequences in antibodies derived from a second, different mammalian species.

The definition of chimeric antibody, however, is not limited to this example. A chimeric 25 antibody is any antibody in which either or both of the heavy or light chains are composed of combinations of sequences mimicking the sequences in antibodies of different sources, whether these sources are differing classes, differing antigen 30 responses, or differing species of origin, and whether or not the fusion point is at the variable/constant boundary. For example, chimeric antibodies can include antibodies where the framework and complementarity-determining regions 35 are from different sources. For example, non-human CDRs are integrated into human framework regions

linked to a human constant region to make "humanized antibodies." See, for example, PCT Application Publication No. WO 87/02671, U.S. Patent No. 4,816,567, EP Patent Application 0173494, Jones, et al., *Nature* 321:522-525 (1986) and Verhoeyen, et al., *Science* 239:1534-1536 (1988), all of which are incorporated by reference herein.

A "human-like framework region" is a framework region for each antibody chain, and it usually comprises at least about 70 or more amino acid residues, typically 75 to 85 or more residues. The amino acid residues of the human-like framework region are at least about 80%, preferably about 80 to 85%, and most preferably more than 85% homologous with those in a human immunoglobulin.

The term "humanized" or "human-like immunoglobulin" refers to an immunoglobulin comprising a human-like framework region and a constant region that is substantially homologous to a human immunoglobulin constant region, e.g., having at least about 80% or more, preferably about 85 to 90% or more and most preferably about 95% or more homology. Hence, most parts of a human-like immunoglobulin, except possibly the CDRs, are substantially homologous to corresponding parts of one or more native human immunoglobulin sequences.

"Hybrid antibody" refers to an antibody wherein each chain is separately homologous with reference to a mammalian antibody chain, but the combination represents a novel assembly so that two different antigens are recognized by the antibody. In hybrid antibodies, one heavy and light chain pair is homologous to that found in an antibody raised against one epitope, while the other heavy and light chain pair is homologous to a pair found in an antibody raised against another epitope. This

results in the property of multifunctional valency or multivalency, i.e., ability to bind at least two different epitopes simultaneously. Such hybrids may, of course, also be formed using chimeric 5 chains.

The present invention encompasses, inter alia, a chimeric antibody, including a hybrid antibody or a humanized or human-like antibody. It also encompasses a recombinant DNA sequence encoding 10 segments of said antibody or any peptide specific for a *trk* receptor protein. Variants of these sequences are also included, such as substitution, addition, and/or deletion mutations, or any other sequence possessing substantially similar binding 15 activity to the sequences from which they are derived or otherwise similar to.

For this invention, an immunoglobulin, antibody or other peptide is specific for a *trk* receptor protein if the immunoglobulin antibody or 20 peptide binds or is capable of binding *trk* receptor protein as measured or determined by standard antibody-antigen or ligand-receptor assays, for example, competitive assays, saturation assays, or standard immunoassays such as ELISA or RIA. This 25 definition of specificity applies to single heavy and/or light chains, CDRs, fusion proteins or fragments of heavy and/or light chains, that are also specific for *trk* protein if they bind *trk* protein alone or if, when properly incorporated into 30 immunoglobulin conformation with complementary variable regions and constant regions as appropriate, are then capable of binding *trk* protein.

In competition assays the ability of an 35 antibody or peptide fragment to bind an antigen is determined by detecting the ability of the peptide

to compete with the binding of a compound known to bind the antigen. Numerous types of competitive assays are known. Alternatively, assays that measure binding of a test compound in the absence of 5 an inhibitor may also be used. For instance, the ability of a molecule or other compound to bind the trk receptor protein can be detected by labelling the molecule of interest directly or it may be unlabelled and detected indirectly using various 10 sandwich assay formats. Numerous types of binding assays such as competitive binding assays are known (see, e.g., U.S. Patent Nos. 3,376,110, 4,016,043, and Harlow and Lane, *supra* which are incorporated herein by reference). Assays for measuring binding 15 of a test compound to one component alone rather than using a competition assay are also available. For instance, immunoglobulins can be used to identify the presence of the trk receptor protein. Standard procedures for monoclonal antibody assays, 20 such as ELISA, may be used (see, Harlow and Lane, *supra*). For a review of various signal producing systems which may be used, see, U.S. Patent No. 4,391,904, which is incorporated herein by reference.

25 Further, the specificity of the immunoglobulin peptides can be determined by their affinity for the trk receptor. Such specificity exists if the dissociation constant ( $K_D = 1/K$ , where  $K$  is the affinity constant) of the peptides is < 30  $1\mu\text{M}$ , preferably <  $100\text{ nM}$ , and most preferably <  $1\text{ nM}$ . Immunoglobulins typically have a  $K_D$  in the lower ranges.  $K_D = [R-L]/[R][L]$  where  $[R]$ ,  $[L]$ , and  $[R-L]$  are the concentrations at equilibrium of the receptor ( $R$ ), ligand or peptide ( $L$ ) and 35 receptor-ligand complex ( $R-L$ ), respectively. Typically, the binding interactions between ligand

or peptide and receptor or antigen include reversible noncovalent associations such as electrostatic attraction, Van der Waals forces and hydrogen bonds.

5       Other assay formats may involve the detection of the presence or absence of various physiological or chemical changes that result from the interaction, such as down modulation, internalization or an increase in phosphorylation as  
10      described in *Receptor-Effector Coupling - A Practical Approach*, ed. Hulme, IRL Press, Oxford (1990).

15      A preferred peptide specific for trk receptor protein induces an increase in the phosphorylation of the trk receptor protein when placed in contact with cells expressing the trk receptor protein. A molecule that induces an increase in the phosphorylation of trk receptor protein is one that causes a detectable increase in  
20      the incorporation of phosphate into the protein over that which occurs in the absence of the molecule. Typically this detectable increase will be a two-fold or greater increase in phosphorylation, preferably greater than a three-fold increase over  
25      controls. Phosphorylation may be measured by those methods known in the art for detecting phosphorylation of receptors. See, for example Cooper, et al., *Methods in Enzymology* 99:387-402 (1983); Antoniades and Pantazis, *Methods in Enzymology* 147:36-40 (1987); and Lesniak, et al., *Methods in Enzymology* 150:717-723 (1987), which are all incorporated by reference herein.

30      Typically, phosphorylation can be measured by *in vivo* phosphorylation of intact cells (Lesniak, 35 *supra*) or by an *in vitro* autophosphorylation reaction (Antoniaides, *supra*). For measuring *in vivo*

phosphorylation, for example, assays may be conducted where cells bearing the trk receptor protein are placed into contact with radioactive labelled phosphate. To detect phosphorylation of 5 the trk receptor protein receptor in the *in vivo* assay, it is advantageous to incubate the test cells for about 12 to about 18 hours, with the labeled phosphate. The cells are divided into two or more batches, where some are exposed to the molecule 10 expected to increase the phosphorylation of the receptor and some are separated out as controls. The aliquots are subsequently immunoprecipitated, the receptor is recognized, for example, by SDS polyacrylamide gel or autoradiography methods, and 15 an increase in phosphorylation is considered statistically significant when there is a two-fold or greater increase in the background of the aliquot exposed to the test molecule over the control aliquots.

20 To measure *in vitro* autophosphorylation, for example, cells or cell extracts may be incubated in the presence or absence of the peptide specific for trk receptor. Following immunoprecipitation with an anti-trk receptor antibody, the immune 25 complex may be incubated with  $\gamma^{32}\text{P}$ -ATP and analyzed by SDS-PAGE autoradiography. For methods for demonstrating trk receptors and for phosphate labelling studies, *in vitro* and *in vivo*, see *Receptor-Effectuator Coupling: A Practical Approach*, 30 E.C. Hulme, ed., chapter 8, Oxford Univ. Press (1990), incorporated by reference herein.

Activation of the trk receptor can be evaluated not only by detecting phosphorylation or an increase in phosphorylation, but also by other 35 means. For example, neuron survival counts or differentiation studies, such as dendritic

outgrowth, collateral sprouting and axon branching, also indicate that an activation of the *trk* receptor has occurred. Additionally, the artisan could observe for signs associated with synaptogenesis and 5 changes in the regulation of neurotransmitter synthesis.

Another general method of evaluating for activation of the *trk* receptor relates to identifying complex formation with signaling 10 substrates. For instance, a *trk*-phospholipase C complex has been known to form after *trk* receptor activation. An immunoprecipitation study can detect the phospholipase C associated with the receptor complex. Additionally, it is thought that other 15 proteins exist in complex formation with *trk* receptor activation and that all of such proteins are not yet fully identified or characterized. The above method of detection of receptor activation can be applied to whole cells, tissue and tumor samples. 20 See, for example, Vetter, et al., *PNAS* 88:5650-5654 (July 1991), incorporated by reference herein.

Another such method which has the advantage of requiring a small amount of tissue involves detecting activation of the *trk* receptor by 25 identifying certain intermediate-early gene products. These gene products can be evaluated for by RNA analysis or immunohistochemistry and are produced by certain genes which are activated about 30 minutes after *trk* receptor activation. See 30 Collazo, et al., *Neuron* 9:643-656 (October 1992), incorporated by reference herein. One can evaluate for the presence of these short-lived regulatory proteins in the cell nucleus. The regulatory protein is used as a marker for phosphorylation 35 induction. In this method, a sample such as a tissue slice is prepared and an immunoglobulin of

the invention is applied to the tissue slice. Cells which have had their *trk* receptors activated in response to the immunoglobulin application will have demonstrable intermediate-early gene products (such as *fos*) in their nucleus. Another antibody which is specific for the protein being used as a marker is then applied to the tissue preparation to allow complex formation. Complex formation is detected by means well known in the art to decide whether *trk* activation has occurred.

An agonist of a receptor is a substance, such as an immunoglobulin, which activates the receptor. Thus, to identify an agonist, one can evaluate for receptor activation as discussed herein.

In embodiments wherein blocking of a *trk* receptor is desired, binding of the immunoglobulin to the receptor can be evaluated as described above in the presence of the preferred neurotrophin ligand, but activation will not occur. Thus, phosphorylation does not increase and evaluations of effect or function (e.g., neuron survival) show no significant enhancement. For instance, a cancer such as a neuroblastoma may grow in response to activation of a *trk* receptor. Thus, treatment with a monovalent immunoglobulin according to the invention could assist with therapy by slowing or stopping tumor growth by blocking the receptor.

To identify antibodies with the desired specificity a number of well-defined techniques, such as their ability to stain neurons via histochemical means, to react with intact neurons on a Fluorescence-activated cell sorter (FACS), or to react with the purified *trk* protein in either an immunoprecipitation assay or in a Western blot assay, are known.

Using standard methods that are well known in the art, the variable regions and CDRs may be derived from a hybridoma that produces a monoclonal antibody that is specific for a *trk* receptor. The 5 nucleic acid sequences of the present invention capable of ultimately expressing the desired chimeric antibodies can be formed from a variety of different nucleotide sequences (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and 10 components (e.g., V, J, D, and C regions), as well as by a variety of different techniques. Joining appropriate genomic sequences is presently a common method of production, but cDNA sequences may also be utilized (see, European Patent Publication No. 15 0239400 and Reichmann, L., et al., *Nature*, 332:323-327 (1988), both of which are incorporated herein by reference).

A similar approach can be taken to isolate and subclone the sequences encoding the constant 20 regions of the heavy and light chains that originate from another mammalian species. The enhancers to the heavy and light chain can be included in the isolated heavy chain fragments, or can alternatively be isolated and subcloned.

25 Human constant region DNA sequences are preferably isolated from immortalized B-cells, see e.g., Heiter, et al., *Cell*, 22:197-207 (1980), incorporated by reference herein, but can be isolated or synthesized from a variety of other 30 sources. The nucleotide sequence of a human immunoglobulin C<sub>1</sub> gene is described in Ellison, et al., *Nucl. Acid. Res.*, 10:4071 (1982); Beidler, et al., *J. Immunol.*, 141:4053 (1988); Liu, et al., *Proc. Natl. Acad. Sci. USA*, 84:3439 (1987) (all 35 incorporated by reference herein).

The CDRs for producing the immunoglobulins of the present invention preferably are derived from monoclonal antibodies capable of binding to the desired antigen, trk receptor protein, and produced 5 in any convenient mammalian source, including, mice, rats, rabbits, hamsters, or other vertebrate host cells capable of producing antibodies by well known methods. Suitable source cells for the DNA sequences and host cells for immunoglobulin 10 expression and secretion can be obtained from a number of sources, such as the American Type Culture Collection ("ATCC") ("Catalogue of Cell Lines and Hybridomas," Fifth edition (1985) Rockville, Maryland, U.S.A., which is incorporated herein by 15 reference).

In addition to the antibody peptides specifically described herein, other "substantially homologous" modified immunoglobulins can be readily designed and manufactured utilizing various 20 recombinant DNA techniques known to those skilled in the art. Modifications of the genes may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see, Gillman and Smith, *Gene*, 8:81-97 (1979) and Roberts, S., et al., 25 *Nature*, 328:731-734 (1987), both of which are incorporated herein by reference). Alternatively, polypeptide fragments comprising only a portion of the primary antibody structure may be produced, which fragments possess binding and/or effector 30 activities.

The cloned variable and constant regions can be isolated from plasmids and ligated together into a mammalian expression vector, such as pSV2-neo, and pRSV-gpt, to form a functional 35 transcription unit. These expression vectors can then be transfected into host cells. Mouse myeloma

cells, such as SP 2/0 or P3X cells, are a preferred host because they do not secrete endogenous immunoglobulin protein and contain all of the components used in immunoglobulin expression.

5 Myeloma cells can be transfected using appropriate techniques as described above.

Other types of promoters and enhancers specific for other host cells are known in the art. See, Kameyoma, K., et al., *supra*. For example, the 10 DNA sequence encoding the chimeric antibody amino acid sequence can be linked to yeast promoters and enhancers and transfected into yeast by methods well known in the art. See, Kriegler, *supra*.

This same approach can be taken to isolate 15 the *trk* receptor specific CDRs from one source such as one mammalian species and the framework regions of another source, such as a different mammalian species. The CDRs can then be ligated to the framework regions and constant regions to form a 20 chimeric antibody. See, PCT No. GB88/00731 (1989), which is incorporated by reference. The CDRs could be cloned in an expression vector comprising, for example, human framework and constant regions.

Another example is a recombinant DNA 25 sequence comprising the heavy and/or light chain CDR1, CDR2, and CDR3 of one species, such as mouse, and the framework regions of human heavy chain to encode an antibody specific for *trk*. Other possibilities include using CDRs specific for *trk*; 30 using part of the variable region encompassing CDR1 and CDR2 from one mammalian species, and then ligating this sequence to another encoding the framework portions of a second mammalian species to the CDR3 of the first; or transfecting a host cell 35 line with a recombinant DNA sequence encoding a *trk* specific heavy chain CDRs derived from a first

mammalian species, interspersed within the framework of a second mammalian species with a light chain containing a variable region DNA sequence derived from the first species and the constant region 5 derived from the second species.

Antibodies may be expressed in an appropriate folded form, including single chain antibodies, from bacteria such as *E. coli*. See, Pluckthun, *Biotechnology*, 9:545 (1991); Huse, et 10 al., *Science*, 246:1275 (1989) and Ward, et al., *Nature*, 341:544 (1989), all incorporated by reference herein.

For diagnostic purposes, the immunoglobulins may either be labeled or unlabeled. 15 Unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the first antibody, such as antibodies specific for human immunoglobulin constant regions. Alternatively, the antibodies can 20 be directly labeled. A wide variety of labels may be employed, such as radionuclides, fluors, enzymes, enzyme substrates, enzyme co-factors, enzyme inhibitors, ligands (particularly haptens), etc. Numerous types of immunoassays are available and are 25 well known to those skilled in the art.

For methods of the invention, particularly for therapeutic methods, the immunoglobulins can be coupled to another compound for a variety of reasons. For example, such a coupling may enhance 30 transport, absorption, bioavailability and distribution of the immunoglobulin. For instance, the compound to which the immunoglobulin is coupled may make the immunoglobulin less susceptible to breakdown by normal enzymatic activity or it may 35 make the immunoglobulin more transportable to certain physiologic compartments. For example, the

immunoglobulin could be rendered more transportable across the blood brain barrier or perhaps more lipid soluble and thus more likely to be received into tissues with a high lipid content.

5         Also contemplated are those compounds that have designed specificities based upon the CDRs specific to a *trk* protein, such as those described here. Organic compounds may be synthesized with similar biological activity by first determining the  
10 relevant contact residues and conformation involved in *trk* binding by an antibody peptide of this invention. Computer programs to create models of proteins such as antibodies are generally available and well known to those skilled in the art (see  
15 Kabat, et al. *Sequences of Proteins of Immunological Interest*, U.S. Department of Health and Human Services, National Institutes of Health (1987); Loew, et al., *Int. J. Quant. Chem. Quant. Biol. Symp.*, 15:55-66 (1988); Brucolieri, et al.,  
20 *Nature* 335:564-568 (1988); Chothia, et al., *Science* 233:755-758 (1986), all of which are incorporated herein by reference. Commercially available computer programs can be used to display these models on a computer monitor, to calculate the  
25 distance between atoms, and to estimate the likelihood of different amino acids interacting (see, Ferrin, et al., *J. Mol. Graphics* 6:13-27 (1988)). For example computer models can predict charged amino acid residues that were accessible and  
30 relevant in binding and then conformationally restricted organic molecules can be synthesized. See, for example, Saragovi, et al., *Science* 253:792 (1991) .

Other General Definitions.

"Recombinant" means that the subject product is the result of the manipulation of genes by human intervention into new or non-native 5 combinations.

"Restriction endonucleases" and "restriction enzymes" refer to enzymes which cut double stranded DNA at or near a specific nucleotide recognition sequence.

10 Complementary DNA, "cDNA" refers to DNA that is derived from a messenger RNA sequence (mRNA), for example, using reverse transcriptase. Reverse transcriptase is an enzyme that polymerizes DNA using an RNA template.

15 "Transcriptional activating sequences" refer to DNA sequences, such as promoters and enhancers, that activate transcription of a gene. Such sequences, in a proper host, drive transcription of a correctly positioned DNA sequence 20 encoding a peptide. For example, the  $\kappa$  chain promoter and  $\kappa$  chain enhancer will promote transcription of a correctly positioned DNA sequence in a myeloma or hybridoma host. Other transcriptional regulator sequences will often be 25 useful in analogous circumstances, for example, when deactivation may be desired.

"Coding strand sequence" is the region of a gene that encodes the amino acid sequence of a protein.

30 A "promoter" is a DNA sequence 5' of the protein coding sequences which affects transcriptional activity. RNA polymerase first binds to the promoter to initiate transcription of a gene.

35 An "enhancer" is a DNA sequence that can positively affect transcriptional efficiency. A

preferred enhancer for the sequence encoding a heavy chain variable region of the antibodies described here is that found at base positions 1566 to 1813 on Sequence Listing ID No. 1.

5       A "vector" is a sequence of DNA, typically in plasmid or viral form, which is capable of replicating in a host. A vector can be used to transport or manipulate DNA sequences. An "expression vector" includes vectors which are  
10 capable of expressing DNA sequences contained therein, typically producing a protein product. The coding sequences are linked to other sequences capable of effecting their expression, such as promoters and enhancers. Expression vectors are  
15 capable of replicating in a host in episomal form; others can integrate into a host cell's chromosome. Ideally, the expression vectors have a selectable marker, for example, neomycin resistance, which permits the selection of cells containing the  
20 marker.

An "oligonucleotide" is a polymer molecule of two or more nucleotides including either deoxyribonucleotides or ribonucleotides.

"Host cells" refer to cells which are  
25 capable or have been transformed with a vector, typically an expression vector. A host cell can be prokaryotic or eukaryotic, including bacteria, insect, yeast and mammalian cells.

"Cellular material" or "cellular sample" refer to animal cells or portions thereof which can be, for example, whole cells, parts of cells (e.g., axon fragments or fragments of neurons) and lysates of cells or parts of cells.

Therapy.

A patient having a neurologic condition suspected of being susceptible to treatment with a method of the invention is selected for therapy.

5 Typically, the patient has a neurological condition discussed previously including the neurodegenerative disorders, nervous system cancer and epilepsy. Conditions including ischemia of any of the portions of the nervous system are included. For example, 10 cerebral vascular ischemia and nerve tissue ischemia are appropriate conditions for therapy. The term "ischemia" refers to suboptimal oxygenation of tissue. The term "nerve tissue" refers to any portion of the nervous system of a recipient of a 15 method of the invention. For instance, the central nervous system and peripheral nervous system are included in the term.

Using a therapeutic method of the invention, immunoglobulins are preferably 20 administered to human patients parenterally. Preferably the compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts. The compositions may also include, depending on the formulation desired, 25 pharmaceutically-acceptable, non-toxic carriers or diluents, which are defined as vehicles commonly used to form pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the 30 combination. Examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or 35 formulation may also include additives such as other carriers; adjuvants; or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like. Effective

amounts of such diluent or additive are those amounts which are effective to obtain a pharmaceutically acceptable formulation in terms of solubility biological activity, etc.

5           In therapeutic applications, the dosage of immunoglobulins used in accordance with the invention will vary considerably depending on the condition being treated. The age, weight, and clinical condition of the recipient patient; and the  
10          experience and judgment of the clinician or practitioner administering the therapy are among the factors affecting the selected dosage. Typically, the dosage of immunoglobulin will range from about 1.0 microgram per kilogram per day to about 1  
15          milligram per kg per day for polyclonal antibodies and about 5% to about 10% of that amount for monoclonal antibodies. For example, the immunoglobulin can be administered once daily as an intravenous infusion. Preferably, the dosage is  
20          repeated daily until either a therapeutic result is achieved or until side effects warrant discontinuation of therapy.

Generally, parenteral administration, such as intraventricular, intramuscular and intravenous  
25          administration, is preferred. Intraventricular administration refers to putting the immunoglobulin into any of the cavities of the nervous system including the left and right lateral ventricles, the third ventricle, the cerebral aqueduct, the fourth  
30          ventricle and the central canal. To put an immunoglobulin into any of these cavities usually involves placing a catheter into the cavity and pushing the immunoglobulin through the catheter and into the cavity. The catheter may be removed after  
35          a bolus infusion of the immunoglobulin or, preferably, a pump is implanted in the patient. The

implanted pump pushes the immunoglobulin through the catheter and into the cavity in a predetermined and usually continuous fashion. Administration by an implanted pump technique can bypass certain problems 5 of other methods of parenteral administration such as difficulties in physiologic transport across the blood brain barrier.

Therapeutic benefit includes any of a number of subjective or objective factors indicating 10 a response of the condition being treated. For instance, some subjective symptoms of neurodegenerative disorders include pain, change in sensation including decreased sensation, muscle weakness, coordination problems, imbalance, 15 neurasthenia, malaise, decreased reaction times, tremors, confusion, poor memory, and uncontrollable movement. Frequently objective signs, or signs observable by the physician or the health care provider, overlap with subjective signs. Examples 20 include the physician's observation of signs such as decreased reaction time, muscle fasiculations, tremors, rigidity, spasticity, muscle weakness, poor coordination, poor memory, disorientation, dysphasia, dysarthria, and imbalance. Additionally, 25 objective signs can include laboratory parameters such as the results of blood tests, biopsies and electrical studies such as electromyographic data. Additionally, nerve conduction studies can be performed to provide an objective criterion to 30 evaluate the effect of therapy.

An example of an objective study which could show a therapeutic benefit in response to the methods of the invention is comparative biopsy. For instance, a nervous system cancer can be initially 35 diagnosed and classified by a biopsy as is well known in the art. Subsequently, after a treatment

using a method of the invention, a biopsy can be repeated. Parameters of the biopsy of the nerve cancer which could indicate improvement in response to the invention include an increased level of 5 differentiation of the tumor as shown in the biopsy material. Additionally, growth markers or indicia of the speed of cell growth can be useful parameters to follow. For instance, a decrease in cell growth as noted by a decrease in thymidylate synthase 10 activity has been correlated with decreased growth of certain tumors. Such a method could apply to the invention wherein a biopsy taken after a treatment with the invention is evaluated and which may show decrease in thymidylate synthase activity thus 15 implying a decrease in tumor growth rate. Evaluation by biopsy applies to other neurologic conditions in addition to cancer. For instance, a biopsy can be useful in evaluating peripheral neuropathies and their response to treatment. The 20 biopsy can be evaluated by a variety of methods known in the art such as histologic staining and analysis as well as by methods of the invention such as labeling with an immunoglobulin of the invention and applying histochemical techniques.

25 Also, macroscopic methods of evaluating the effects of the invention can be used, such as evaluating the tumor size or bulk clinically or by X-ray or other studies which may be invasive or noninvasive. Further examples of evidence of a 30 therapeutic benefit include clinical evaluations for memory improvement, increased performance speed of defined tasks as compared to pretreatment performance speeds, and nerve conduction velocity studies. For example, it has been demonstrated that 35 experimental animals deficient in NGF also suffer from poor memory retention. Evaluation of features

such as memory, speed of performing defined tasks, and nerve conduction studies could also be used to indicate that appropriate *trk* receptors have been activated. Any of the features relating to 5 therapeutic benefits can be examples of improved neuronal function.

*TrkA*, a tyrosine kinase receptor, is an essential component of the NGF response pathway. The binding of NGF to the receptor induces receptor 10 autophosphorylation and activation of intracellular signaling pathways, resulting in diverse biological effects. Described herein is the preparation of antibodies against the entire extracellular domain of rat *trkA* produced using a baculovirus expression 15 system. These antibodies specifically recognize rat *trkA* on antigen blots and in immunoprecipitations.

Both IgG and Fab fragments of the invention block binding of NGF to *trkA* expressed by 20 the PC12 cell line. In NGF binding studies herein, anti-*trkA* and anti-low affinity NGF receptor (anti-LNGFR) IgG inhibited, essentially all binding of NGF. The results imply that at least 97% of the NGF 25 binding sites on PC12 cells are accounted for by *trkA* and the LNGFR. The binding data also argue that all low affinity NGF binding sites on PC12 cells reflect interactions with the LNGFR, while all high affinity sites are *trkA*-dependent. A fraction 30 of the high affinity sites seem to require both *trkA* and the LNGFR.

While the monovalent anti-*trkA* Fab fragments of the invention inhibited the biological effects of NGF, such as induction of tyrosine phosphorylation and survival and neurite outgrowth 35 of sympathetic neurons, the IgG preparation surprisingly was not effective as an inhibitor.

Instead, the IgG fraction by itself was almost as effective as NGF at stimulating receptor activation and cell survival. Thus, it appears that oligomerization of trkA by antibody-induced 5 crosslinking produces cellular effects of NGF.

Development of an antiserum to the rat trkA receptor.

Generation of antisera to both the LNGFR 10 and trkA receptors allows the expression and function of each to be studied individually. Several monoclonal antibodies and the REX anti-LNGFR polyclonal antibody have been used to characterize the LNGFR receptor, but an antiserum of equivalent 15 specificity to trkA has not been available previously. The invention is illustrated by a bivalent IgG antibody, RtrkA.EX, which is highly specific for trkA. No cross-reaction with the closely related trkB receptor on immunoblots was 20 detected.

A discrete immunohistochemical staining pattern in mouse brain consistent with what is known about trkA gene expression has been seen. The RtrkA.EX antibody recognizes the rat trkA receptor in its 25 native state, as judged by immunoprecipitation analysis, and is therefore useful in a variety of experiments aimed at improved understanding of trkA and NGF responsiveness in neurons. The anti-trkA IgG promoted NGF-like cellular responses even in the 30 absence of NGF, presumably through antibody-dependent receptor cross-linking.

An antibody of the invention can inhibit NGF binding, as well as neuronal responses to NGF, when Fab fragments were employed. NGF binding 35 experiments demonstrated that monovalent Fab fragments prepared from the RtrkA.EX antibody

inhibit NGF binding to *trkA* (Fig. 1), and subsequently inhibit downstream cellular NGF responses, such as increases in tyrosine phosphorylation and survival of sympathetic neurons 5 (Fig. 3).

The use of monovalent Fab fragments for *trkA* receptor blocking can be a useful method for confirming or disproving in an *in vivo* context some of the functions assigned to NGF based on *in vitro* 10 studies. In fact, this could be a general approach to studying the roles of *trk* receptors during development in many species. Since it is thought that several of the functions of *trk* receptors are based on competition for limiting amounts of 15 neurotrophin in the animal (Barde, 1989), blocking a large number of the receptors by Fab could yield dramatic effects during development. Data herein indicates blockage of sympathetic survival only at low concentrations of NGF and high concentrations of 20 Fab, which is likely due to the differences in receptor affinity. However, given that *in vivo* concentrations of NGF are much lower than those used in culture, it is possible that this Fab preparation would be an effective means of blocking *trkA* 25 function in developing rats or mice.

An "Fab" fragment comprises a light chain and the N-terminus portion of the heavy chain to which it is linked by disulfide bonds. It has a molecular weight of approximately 50 kD and contains 30 a single antigen binding site. Fab fragments may be obtained from *F(ab')*<sub>n</sub> fragments by limited reduction, or from whole antibody by digestion with papain in the presence of reducing agents (see Harlow and Lane, *supra*).

Ligand-independent activation of trkA by RtrkA.EX.

While the IgG and Fab preparations of the RtrkA.EX sera are equivalent in their ability to inhibit NGF binding to trkA, as judged by binding assays using radiolabeled ligand, the RtrkA.EX IgG is almost as effective as NGF in activating trkA and downstream signaling pathways (Fig. 4).

Evidence has been presented that the trkA receptor functions as a homooligomer, probably a dimer, in signal transduction (Jing, et al., 1992). Therefore, it is likely that the bivalent RtrkA.EX IgG promotes dimerization or oligomerization sufficient to cause transphosphorylation of the receptor and subsequent activation of the NGF signal transduction pathway.

The RtrkA.EX antibody at saturating concentrations exhibits a somewhat lower survival activity than NGF (Fig. 4). This seems to be an intrinsic property of the receptor-antibody interaction. Because the presence of NGF does not restore the maximal level of survival, the lack of NGF bound to the LNGFR is not likely the cause.

Activation of trkA by RtrkA.EX is a useful method for separating the effects of trkA from those of the LNGFR. In fact, this property can be exploited to differentiate the effects of the three receptors of the trk family, as antibodies have the potential to be of different specificity from the neurotrophins themselves.

For example, in some systems NT-3 has been shown to activate trkC strongly, to activate trkB moderately, and to activate trkA weakly (Cordon-Cardo, et al., Cell. 66:173-83 (1991); Glass, et al., Cell. 66:405-13 (1991); Squinto, et al., Cell. 65:885-93 (1991); Soppet, et al., Cell. 65:895-903 (1991); Lamballe, et al., (1991)). Studies designed

to analyze the various functions of *trkC* by using NT-3 as ligand may also be measuring its effects on *trkB* or *trkA*. An activating antibody to *trkC*, however, would produce effects which are 5 attributable solely to *trkC*.

*TrkA* activity, but not LNGFR activity, is required for sympathetic neuron survival in vitro.

The experiments herein evaluate the 10 relative contributions of LNGFR and *trkA* in high affinity NGF binding and in the NGF-dependent survival of sympathetic neurons. One of the models of LNGFR function holds that LNGFR and *trkA* form a high-affinity heterodimer, and that the LNGFR 15 participates in the NGF signal transduction pathway (Hempstead, et al., 1991; Berg, et al., 1991). It now seems clear that activation of *trkA* is necessary and sufficient to achieve most cellular NGF effects, at least under *in vitro* culture conditions. This is 20 born out by the finding herein that in the absence of NGF the R*trkA*.EX IgG facilitates survival and differentiation of both sympathetic neurons and PC12 cells by activating *trkA*. Several previous observations also support this conclusion. Evidence 25 that *trkA* is a necessary component of the NGF responsive pathway in PC12 cells comes from studies of the *trkA*-deficient cell line PC12nnr5, where it was shown that its lack of NGF response could be rectified by the reintroduction of *trkA* (Loeb, et 30 al., *Cell*. 66:961-6 (1991)).

There are several lines of evidence which suggest that the LNGFR does not play a crucial role in NGF signal transduction. The anti-LNGFR polyclonal antibody REX was able to block binding of 35 NGF to LNGFR completely, yet had no obvious effect on the biological activities of NGF in culture

(Weskamp and Reichardt, 1991). In agreement with this result, a mutated NGF which had lost its ability to bind to LNGFR was able nevertheless to support neurite outgrowth from PC12 cells and 5 survival of neonatal sympathetic neurons (Ibáñez, et al., *Cell.* 69:329-41 (1992)). A recent study, published after the completion of the present work, examined the activity in PC12 cells of a chimeric receptor consisting of the *trkA* intracellular kinase 10 domain fused to the tumor necrosis factor receptor extracellular domain, and found that treatment of the modified PC12 line with tumor necrosis factor could promote PC12 process outgrowth, presumably without interaction with the LNGFR (Rovelli, et al., 15 *Proc. Natl. Acad. Sci. USA* 90:8717-8721 (1993)).

In each of the above examples, it is assumed that the LNGFR is not contributing to the NGF response if the LNGFR is not binding ligand, something which is difficult to prove using those 20 models. Jaenisch and colleagues have addressed this issue by creating a mouse strain in which the gene for the LNGFR has been inactivated (Lee, et al., *Cell.* 69:737-49 (1992)). The resulting mice were viable and fertile. Examination of the nervous 25 system revealed a loss of some sensory innervation and a defect in heat sensitivity, although the sympathetic innervation was apparently normal. Examination of the *in vitro* sensitivity to NGF of the trigeminal sensory neurons and sympathetic 30 neurons has recently been reported; while a three- to four-fold decrease in the NGF dose-response was measured for the sensory neurons, no differences were detected between the LNGFR-deficient and wild type sympathetic neurons (Davies, et al., *Neuron.* 35 11:565-574 (1993)). Thus for at least some of the targets of NGF, the LNGFR is not required either in

an NGF-bound or unbound state for NGF to achieve its effects.

An interesting model proposed recently has the LNGFR acting in a dominant fashion: when the receptor is bound by ligand, it is inactive, but when unbound it is free to activate a cellular pathway leading to apoptotic cell death (Rabizadeh, et al., 1993). Evidence herein argues against this model for sympathetic neurons, as activation of trkA by RtrkA.EX in the absence of NGF (and therefore when the LNGFR is presumably unbound) could support sympathetic neuron survival, and the combination of RtrkA.EX and NGF did not yield much more survival than the antibody alone. At a minimum, the activation of the trkA signaling pathway overrides the putative LNGFR-dependent apoptotic pathway. As the model suggests that the LNGFR works in a dominant fashion to cause apoptosis, it does not easily explain the deficits observed in the LNGFR-deficient mouse. If the dominant model of LNGFR action is correct, the deletion of the LNGFR gene might actually be expected to increase the number of cells in certain populations, rather than eliminate them, and would be unlikely to lead to the observed deficit in sensory innervation.

The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the operating conditions, materials, procedural steps and other parameters of the system described herein may be further modified or substituted in various ways without departing from the spirit and scope of the invention. Thus the invention is not limited by the preceding description and the following examples, but rather by the appended claims.

EXAMPLESExample 1: Preparation of an antibody against the extracellular domain of rat trkA

5 To probe the function of the trkA receptor biochemically and biologically, a polyclonal antibody was developed to the extracellular domain of trkA.

10 Rabbit polyclonal antisera recognizing rat trkA were generated by using as antigen synthetic peptides derived from the rat trkA amino acid sequence coupled to keyhole limpet hemagglutinin by m-maleimidobenzoylsulfosuccinimide ester (Pierce Chemical Co.). One of the antisera (rtrkA.EX2) was 15 raised against the peptide CSVLNFTSFIFTQFLESALTNETMRH (SEQ ID No.: 1) (amino terminal cysteine + trkA amino acids 322 to 346) and recognized the extracellular domain of trkA by immunoblot.

20 Another antibody (rtrkA.cyt) was raised against a peptide corresponding to the carboxy-terminal end of the rat trkA receptor (CARLQALAQAPPSSYLDVLG; (SEQ ID No.: 2) amino terminal cysteine + trkA amino acids 782 to 799) and was 25 subsequently affinity purified on a column including the same peptide coupled to thiopropyl-Sepharose CL-6B (Pharmacia LKB Biotechnology).

Generation of a third trkA antiserum, denoted RtrkA.EX antibody and abbreviated RTA or 30 RtrkA.Ex, is outlined below. Briefly, cDNAs encoding rat trkA were isolated from a PC12 cDNA library constructed in the plasmid vector CDM8. Ten cDNAs were isolated, and sequence analysis revealed that several of these contained the entire rat trkA 35 coding sequence.

cDNA cloning. A PC12 cDNA library was constructed in the plasmid vector CDM8 using nonpalindromic adaptors (Invitrogen Corp., San Diego, California) essentially as described (Seed, 5 B., *Nature*, 329, 840-842 (1987); Aruffo, A. and Seed, B., *Proc. Natl. Acad. Sci. USA*, 84, 8573-8577 (1987)). A probe for the rat *trkA* cDNA was generated from cDNA derived from the human cell line K562 (Martin-Zanca, et al., 1989) using reverse 10 transcription - polymerase chain reaction (RT-PCR) and the primers

5' GGC CGA ATT CGC CCG GCG CAG AGA ACC TGA  
CTG AGC 3' (SEQ ID No.: 3) and

5' GGC CGA ATT CAT GTG CTG TTA GTG TCA GGG  
15 ATG GGG 3' (SEQ ID No.: 4), which yields a 1027 base pair (bp) fragment (coding for amino acids 63 to 397) derived from the region of the transcript encoding the extracellular domain.

Bacterial colonies harboring rat *trkA*- 20 containing plasmids were isolated using colony hybridization (Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, 2d ed. (1989)). cDNA inserts were recloned into Bluescript vectors and sequenced using the dideoxynucleotide-termination method 25 (Sequenase; United States Biochemical Co.). The sequence obtained agreed with that published previously (Meakin, S. O., Suter, U., Drinkwater, C. C., Welcher, A. A. and Shooter, E. M., *Proc. Natl. Acad. Sci. USA*, 89, 2374-8 (1992)), with the 30 exception of a slightly shorter 5' untranslated region.

A truncated *trkA* expression cassette containing the entire extracellular domain of rat *trkA* was generated by polymerase chain reaction (PCR) and its DNA sequence verified. The cassette was subsequently cloned into a baculovirus transfer 35

vector from which recombinant viruses were isolated through standard protocols.

Construction of a baculovirus strain

5 expressing a rat trkA truncation. PCR was used to generate a version of the rat trkA cDNA which could direct expression of a truncated form of the receptor. The primers used were:  
5' CCG AAT TCC ATG GCG CGA GGC CAG CGG CAC GGG CAG  
10 CTG G 3' (SEQ ID No.: 5) (5' end of cassette) and  
5' CCG AAT TCC ATG GCT ATT ATT CGT CCT TCT TCT CCA  
CTG GGT CTC 3' (SEQ ID No.: 6) (3' end of cassette).

15 The resulting DNA construct was flanked by EcoRI and NcoI restriction sites, and contained the DNA sequence between the presumptive start methionine codon and the glutamic acid codon before the transmembrane domain (therefore encoding amino acids 1 to 416; called RtrkA.t).

20 The construct was cloned into the baculovirus transfer vector pVL1393 (Webb, N. R. and Summers, M. D., *Technique.*, 2, 173-188 (1990)) using EcoRI sites. The resulting plasmid was used to transfer the RtrkA.t construct into a linearized 25 baculovirus AcMNPV genome (Invitrogen Corp.), and purified recombinant viruses which express the truncated form of the trkA receptor were isolated using standard methods (Summers and Smith, *A Manual of Methods for Baculovirus Vectors and Insect Cell* 30 *Culture Procedures*, Texas Agricultural Experimental Institute (1987); Webb and Summers, 1990). Recombinant viruses were identified using PCR and oligonucleotide primers specific for RtrkA.t construct and the AcMNPV genome (Invitrogen Corp.) 35 Infections of Sf9 cells (ATCC No. CRL 1711) with the recombinant virus resulted in the

production of an approximately 55 kilodalton (kD) product which was secreted into the medium. The expression of the truncated *trkA* protein was monitored by immunoblotting with an anti-*trkA* peptide antiserum, and the protein was purified.

Purification of RtrkA.EX protein and generation of the RtrkA.EX antibody. Large scale infections with the RtrkA.EX-expressing baculovirus 10 were performed using the Sf9 cell line (the gift of W. Mobley) grown in Sf9 II SFM medium (Gibco/BRL, Life Technologies). The levels of RtrkA.EX protein throughout expression and purification procedures were measured by antigen blot with the rtrkA.EX2 15 anti-peptide antibody.

For purification, 1.2 liters (l) of Sf9 cells were infected with 160 milliliters (ml) of high titer viral stock, and two days post-infection, the supernatant was harvested and loaded onto a 10 20 ml lentil lectin-Sepharose column (Pharmacia/LKB Biotechnology).

After washing with 500 mM NaCl and 5 mM Tris-Cl at pH 7.5, protein was eluted with 5 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.5 M methyl- $\alpha$ -D-mannopyranoside (Sigma Chemical Corp.). The eluate 25 was dialyzed into 20 mM Tris-Cl pH 8.0, concentrated by pressure on a YM30 membrane (Amicon), and loaded onto a MonoQ column (1 ml; Pharmacia/LKB Biotechnology).

30 After washing the column with 20 mM Tris-Cl at pH 8.0, the column was developed with a linear gradient to 20 mM Tris-Cl, pH 8.0, 1 M NaCl. The RtrkA.EX protein eluted in a peak at approximately 200 mM NaCl, and ran on sodium dodecyl sulfate-35 polyacrylamide gel electrophoresis (SDS-PAGE) as an

overlapping doublet of approximately 55 kD molecular weight, with a typical yield of 500  $\mu$ g.

Both of the doublet bands reacted strongly with the rtrkA.EX2 antibody, indicating that each 5 was derived from the trkA expression vector but differed by post-translational modification such as glycosylation. The identity of the purified protein was confirmed by the amino acid sequence analysis of two peptides derived from a trypsin digestion of the 10 preparation.

The protein's identity was confirmed by determining the amino acid sequences of two tryptic peptides derived from it. The truncated trkA protein was subsequently used as an immunogen to 15 raise rabbit polyclonal antisera. This antibody is referred to herein as the RtrkA.EX antibody (abbreviated as RTA).

The purified protein was used to immunize a rabbit with an initial injection of 175 micrograms 20 ( $\mu$ g) of protein; subsequent boosts were 50  $\mu$ g each. IgG was prepared from the resulting sera by affinity chromatography on protein-A Sepharose by standard methods (Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New 25 York (1988)).

Immunoblots and immunoprecipitations. The ability of the RtrkA.EX sera to recognize native rat trkA was tested by immunoprecipitation analysis, 30 using lysates of COS cells surface-labeled with biotin following transfection with CDM8/rat trkA, or with vector alone as control.

Lysis buffer contained: 150 mM NaCl; 50 mM Tris-Cl, pH 7.6; 1% Triton X-100; 0.1% sodium 35 dodecyl sulfate; 1 mM ethylenediaminetetraacetic acid; 1 mM phenylmethylsulfonyl fluoride; 50 mM NaF;

and 10 mM sodium pyrophosphate. When the lysates were to be probed for phosphotyrosine, the lysis buffer contained 0.1 mM sodium orthovanadate in addition.

5                   Extracts were prepared by incubating cells with lysis buffer on ice for 15 minutes; insoluble material was removed with a 10,000 rpm centrifugation at 4°C for ten minutes. Extracts were separated on SDS-polyacrylamide gels and 10 transferred to nitrocellulose using standard protocols (Harlow and Lane, 1988).

15                  TrkA immunoprecipitations were performed by adding 2-10 µg of IgG and 30 ml of protein A-Sepharose per sample. After two to three hours at 4°C, the Sepharose was washed four times with lysis buffer. Sepharose-bound proteins were eluted in two times volume of Laemmli SDS sample buffer and loaded on SDS-PAGE for immunoblot analysis.

20                  For biotinylation, COS cell cultures which had been transfected with cDNA constructs two days previously were washed two times with calcium- and magnesium-free phosphate buffered saline (CMF-PBS). CMF-PBS + 100 mM Hepes at pH 8.0 and 360 µg/ml sulfosuccinimidobiotin (Pierce Chemical Corp.) was 25 added and the cultures were incubated for one hour at room temperature. The cultures were washed four times with phosphate buffered saline (PBS) + 5 mM glycine and lysates were prepared as above. The extracts were precleared with protein-A sepharose, 30 and immunoprecipitations were performed as described above.

35                  After immunoprecipitations were performed with either RtrkA.EX, an anti-peptide antibody to the trkA cytoplasmic tail (rtrkA.cyt), or control IgGs, the precipitates were analyzed by blot using a streptavidin-horseradish peroxidase (HRP)

conjugate for detection (Fig. 1A). The HRP-coupled streptavidin was purchased from Zymed Laboratories, Inc.

5 Immunoblots were performed using 80 mM NaCl, 50 mM Tris-Cl at pH 8.0, 0.5% Nonidet P-40 and either 5% nonfat milk or 3% bovine serum albumin. 1% ovalbumin was used when HRP-coupled secondary antibodies were used.

10 The anti-phosphotyrosine monoclonal antibody 4G10, purchased from Upstate Biologicals Inc., was used at 1  $\mu$ g/ml, followed by rabbit anti-mouse antibody, purchased from Organon Teknika Corp., coupled to HRP diluted 1:5000.

15 Streptavidin-HRP was also used at 1:5000 dilution; the alkaline phosphatase coupled secondary antibody (alkaline phosphatase-conjugated goat anti-rabbit antibody obtained from Promega Corp.) was used at 0.1  $\mu$ g/ml and was developed using the BCIP/NBT method (Harlow and Lane, 1988). HRP 20 conjugates were detected with the ECL chemiluminescence protocol (supplied by the manufacturer with the reagent) developed by Amersham Corp.

25 COS cell cultures were transfected with CDM8 vector alone (V) or with CDM8 containing the rat *trkA* cDNA (T) and were subsequently cell surface-labeled with sulfosuccinimidobiotin. The resulting extracts were used for immunoprecipitation as follows: 100  $\mu$ g of extract (CDM8 extract, lane 30 1; CDM8/*trkA* extract, lanes 2-5) were precipitated with the addition R*trkA*.EX IgG (lanes 1 and 5), rat *trkA* cyto-tail IgG (lane 4), nonimmune rabbit IgG obtained from Organon Teknika Corp. (lane 3), or no antibody (lane 2).

35 After precipitation with protein-A Sepharose, the immune complexes were separated on

7.5% SDS polyacrylamide gels, transferred to nitrocellulose, and visualized with peroxidase-coupled streptavidin and the ECL chemiluminescence protocol (Amersham Corp.).

5           RtrkA.EX was able to precipitate the 140 kD trkA protein efficiently (lane 5), as shown by comparison to the same lysate precipitated with an antibody directed against the cytoplasmic tail of trkA (lane 4). A set of weak bands with an  
10 approximate mass of about 110 kD in both lanes were likely immature forms of the trkA receptor which have been transported to the cell surface (Martin-Zanca, et al., 1989) or derived from the 140 kD form of trkA by proteolysis. The trkA products were not  
15 detected in control lysates derived from a vector-only transfection precipitated with RtrkA.EX (lane 1), or in precipitates of trkA-transfected cells using control rabbit IgG (lane 3). Several proteins of lower apparent molecular weight were detected in  
20 each of the precipitates, including controls, and therefore appear to be nonspecific contaminants.

The specificity of the RtrkA.EX antibody was also tested by immunoblot using the method described above. Immunoblotting of cell extracts  
25 from COS cell cultures was done as follows. The antigen blot was derived from a 7.5% PAGE of COS cell lysates (7 µg each) transfected with the CDM8 vector (lane 1), CDM8/rat trkA (lane 2), or CDM8/rat trkB (lane 3). The filter was incubated with 0.5  
30 mg/ml RtrkA.EX IgG, followed by an anti-rabbit-alkaline phosphatase secondary antibody. The expression of the trkB in lane 3 was confirmed by blotting a parallel experiment with an anti-trkB cytoplasmic tail antibody. COS cell cultures were  
35 transfected as above with the rat trkA or rat trkB

cDNAs, or vector alone, and lysates from all three cultures were probed with the RtrkA.EX sera.

Two prominent bands were detected in the lysate of the *trkA* transfected culture, migrating at 5 an approximate molecular mass of 110 kD and 140 kD. No cross-reaction to *trkB* was detected, although it was abundantly expressed, as determined by probing a parallel blot with an antibody against the *trkB* cytoplasmic tail. A faint band was detected in all 10 three lysates, migrating with an approximate molecular mass of 180 kD. This band seemed to be a nonspecific reaction of the sera, as it was seen in untransfected COS cells, as well as other cell lines (including the PC12 cell line). It was not detected 15 by immunoprecipitation, indicating that either it was an intracellular protein and therefore not labeled by the biotinylation reagent, or that it was not recognized by the antibody in an undenatured state.

20

Example 2: RtrkA.EX blocks the binding of NGF to the *trkA* receptor.

From the immunoprecipitation analysis it was clear that the RtrkA.EX antibody can recognize 25 the native *trkA* receptor protein. To determine if the antibody could disrupt the NGF-binding activity of the receptor, and therefore serve as an inhibitor of the receptor's function, the following experiments were done. In this series of 30 experiments, the effects of the antibody preparations were tested in NGF binding assays of the PC12 cell line, known to express both the low affinity NGF receptor LNGFR as well as *trkA*. NGF was purified from male mouse submaxillary gland 35 following the procedure of (Mobley, W. C., Schenker,

A. and Shooter, E. M., *Biochemistry.*, 15, 5543-5552 (1976)) or was the gift of W. Mobley.

Cell culture. PC12 cells (ATCC No. CRL 1721) were maintained in Dulbecco's Modified Eagle's medium (DME-H21) containing 10% fetal calf serum and 5% horse serum on tissue culture plastic. The nnr5 subclone of PC12 (available from Dr. Lloyd Greene, New York University School of Medicine, NYC, NY 10016) and its transfected derivatives were grown in the same medium on a collagen I substrate (Vitrogen 100, Celtrix Pharmaceutical, Inc.). PC12 cells used for outgrowth experiments were treated with NGF in DME-H21 containing 1% horse serum for seven days prior to replating in the same medium supplemented with NGF or antibodies.

A whole cell binding assay containing 200 pM  $^{125}\text{I}$ -NGF was employed to measure the dose-dependent inhibition of binding (Fig. 1A).  $^{125}\text{I}$ -NGF was purchased from Amersham Corp.

Figure 1 shows data indicating that RtrkA.EX IgG and Fab fragments block NGF binding to PC12 cells. Fig. 1A shows a dose response. PC12 cells were incubated with antibodies at the indicated concentration for four hours at 37°C, and binding was initiated by the addition of 200 pM  $^{125}\text{I}$ -NGF. After a one hour incubation, the amount of cell-associated NGF was determined. Antibodies tested were control rabbit IgG, RtrkA.EX IgG, and RtrkA.EX Fab fragments. Fab fragments were prepared from nonimmune rabbit IgG or the RtrkA.EX IgG using papain-agarose (Sigma Chemical Co.) by standard methods (Harlow and Lane, 1988). Nonspecific binding was determined by addition of 10  $\mu\text{g/ml}$  unlabeled NGF, and has been subtracted. Values were

determined in triplicate and are shown as percent control (no antibody addition).

The RtrkA.EX IgG and Fab preparations were able to inhibit the binding of NGF to PC12 cells 5 partially, achieving a maximum inhibition of about 30%. Approximately 125 mg/ml antibody was required to reach this maximal level of inhibition.

Binding Assays. Binding assays were 10 performed with PC12 cells and  $^{125}\text{I}$ -NGF as previously described (Weskamp and Reichardt, 1991). Briefly, antibodies were preincubated with the cells ( $5 \times 10^5$  cells/ml) at 37°C for two or four hours prior to addition of  $^{125}\text{I}$ -NGF; cell-associated NGF was 15 determined after a further 60 minutes at 37°C. Nonspecific binding was determined by addition of 10 mg/ml unlabeled NGF, and ranged from 2-25% of specific binding. Determinations were made in triplicate. The equilibrium binding data from two 20 experiments were combined for the Scatchard analysis (Scatchard, G., *Analys of NY Acad. Sciences* 5:660-672 (1949)), which was performed with the program LIGAND (Munson, P. J. and Rodbard, D., *Anal. Biochem.*, 107, 220-239 (1980)). The Scatchard data 25 are plotted as fmoles bound per  $10^5$  cells (equivalent to a volume of  $2 \times 10^{-4}$  liters).

Furthermore, the data show that the residual NGF binding in the presence of RtrkA.EX was due to binding to the low affinity NGF receptor, by 30 testing saturating concentrations of antibodies to both trkA and the LNGFR (Figure 1B). Here, NGF binding assays on PC12 cells were performed in the presence of RtrkA.EX IgG or Fab, anti-rat LNGFR IgG, or combinations of the antibodies, using the method 35 described above.

The anti-LNGFR antibody (anti-REX; Weskamp and Reichardt, 1991) is an anti-rat polyclonal antiserum raised against the extracellular domain of LNGFR, and has been shown to inhibit NGF binding to 5 that receptor completely.

Fig. 1B shows the additive effects of RtrkA.EX and anti-LNGFR antibodies. PC12 cells were incubated at 37°C for four hours with 500 µg/ml of each indicated antibody, followed by the addition of 10 250 picomolar (pM)  $^{125}\text{I}$ -NGF. After a further 60 minutes at 37°C, the amount of cell-bound NGF was determined. Antibodies tested were: A, control rabbit IgG; B, anti-LNGFR IgG (REX); C, RtrkA.EX IgG (RTA); D, RtrkA.EX Fab fragments; E, anti-LNGFR IgG 15 + RtrkA.EX IgG; and F, anti-LNGFR IgG + RtrkA.EX Fab fragments. Nonspecific binding was determined as in Fig. 1A; values are shown as a percentage of the control (no antibody addition). The values shown are the average of two experiments of triplicate 20 samples and include calculated standard error of the mean.

As shown in Figure 1B, the anti-LNGFR antibody blocked approximately 80% of NGF binding, while the RtrkA.EX IgG or Fab blocked approximately 25% of NGF binding. The combinations of antibodies were able to inhibit almost completely the binding of NGF to PC12 cells, indicating that trkA and the LNGFR account for at least 97% of the NGF binding proteins on PC12 cells.

30 Confirmation of the RtrkA.EX specificity was obtained using NGF cross-linking assays (Weskamp and Reichardt, 1991), where preincubation of the cells with the RtrkA.EX antibody sharply reduced the production of the 160 kD band, previously identified 35 as the trkA  $^{125}\text{I}$ -NGF cross-linked product, without altering the levels of the 100 kD, LNGFR-derived

product (Hosang and Shooter, 1985; Johnson, et al., 1986; Weskamp and Reichardt, 1991; Kaplan, et al., 1991a; Klein, et al., 1991).

To analyze the characteristics of the NGF binding sites remaining in the presence of the anti-LNGFR or -trkA antibodies, equilibrium binding assays were performed from 3.5 to 4000 pM NGF. The results are plotted by the Scatchard method in Figure 2. As is now well known, PC12 cells have NGF binding sites with differing kinetic characteristics, leading to low and high affinity binding sites (Schechter and Bothwell, 1981). This is observed in the biphasic graph of NGF binding determined in the presence of control IgG (Fig. 2, open squares; the binding parameters are presented in Table 1).

Table 1\*

Effects of anti-LNGFR and RTrkA.EX IgG on Equilibrium Binding of  $^{125}$ I-NGF to PC12 Cells

20	Control IgG		anti-LNGFR IgG		RTrkA.EX IgG	
	$K_d$ (M)	Receptors per Cell	$K_d$ (M)	Receptors per Cell	$K_d$ (M)	Receptors per Cell
	$3.8(\pm 1.9) \times 10^{-11}$	$4900 \pm 700$	$9.2(\pm 2.6) \times 10^{-11}$	$2800 \pm 400$	--	--
25	$1.8(\pm 0.7) \times 10^{-9}$	$3400 \pm 3200$	--	--	$1.1(\pm 0.6) \times 10^{-9}$	$28300 \pm 3000$

30 \*Binding parameters derived from the Scatchard analysis shown in Figure 2, as determined by the LIGAND program.

Figure 2 is an analysis of anti-LNGFR- and RtrkA.EX-resistant NGF binding sites. PC12 cells were preincubated with 500  $\mu$ g/ml control rabbit IgG, anti-LNGFR (REX) IgG, or RtrkA.EX (RTA) IgG for two hours at 37°C.  $^{125}$ I-NGF (3.5 pM to 4 nM) was added, and the amount of cell associated NGF determined after one hour at 37°C. Data from two similar experiments were pooled, and are presented in the

form of a Scatchard plot. Nonspecific binding was determined as in Fig. 1A; values were determined in triplicate.

The number and affinity of the two measured NGF binding sites in the presence of control IgG are similar to those previously reported for PC12 cells (Weskamp and Reichardt, 1991). Preincubation with anti-LNGFR IgG blocks all of the low affinity sites, and blocks a fraction of the high affinity sites, as shown previously (Figure 2, diamonds; Weskamp and Reichardt, 1991). In contrast, the data herein show that in the presence of the RtrkA.EX antibody, all of the remaining detectable binding sites are of low affinity (Fig. 2, open circles). These results indicate that all detected high affinity binding sites require trkA. However, this analysis also suggests that there may be two types of high affinity sites, one which is dependent solely on trkA, and one of which requires both trkA and the LNGFR. No evidence was found for high affinity sites solely dependent on the LNGFR.

Example 3: RtrkA.EX Fab fragments inhibit the phosphorylation response to NGF.

PC12 cells respond to NGF rapidly, and after five minutes of exposure, a reproducible burst of tyrosine phosphorylation of many cellular proteins occurs (Maher, P. A., *Proc. Natl. Acad. Sci. USA* 85:6788-6791 (1988)). This effect can be measured by probing blots of cell lysates with anti-phosphotyrosine antibodies. In lane 2 several cellular substrates for NGF-dependent tyrosine phosphorylation are detected after five minutes of NGF treatment (arrows), but not in the absence of NGF (lane 1).

RtrkA.EX Fab fragments block NGF-dependent cellular tyrosine phosphorylation. PC12 cultures were preincubated with 500  $\mu$ g/ml nonimmune Fab (control, lane 3), RtrkA.EX Fab (RTA, lane 4), or no 5 antibody (lanes 1 and 2), for four hours prior to the addition of 5 ng/ml NGF for five minutes (lanes 2-4). The cleared lysates (10  $\mu$ g) were fractionated by 10% SDS-PAGE, blotted, and probed for changes in cellular tyrosine phosphorylation using the 4G10 10 monoclonal, HRP-coupled anti-mouse secondary antibody, and ECL. The positions and relative molecular weights of the marker proteins are shown at the left, and the arrows on the right indicate several prominent proteins which become 15 hyperphosphorylated during the assay.

The ability of the anti-trkA antibody to block this rapid response was tested by pretreating the PC12 cultures with RtrkA.EX Fab fragments, or control nonimmune Fab fragments prior to exposure to 20 NGF. RtrkA.EX Fab fragments were able to block almost completely the phosphorylation response to NGF (lane 4), while control nonimmune Fab fragments did not affect the response (lane 3).

25 Example 4: RtrkA.EX IgG mimics NGF in tyrosine phosphorylation assays.

In contrast to the inhibitory effects of the monovalent RtrkA.EX Fab fragments, the bivalent RtrkA.EX IgG promoted phosphorylation of the same 30 cellular proteins as NGF, even in the absence of NGF.

RtrkA.EX IgG stimulates protein tyrosine phosphorylation in the absence of ligand. PC12 cells were treated for five minutes with growth 35 factors or antibody preparations at 37 C. Lysates were prepared and analyzed for changes in cellular

phosphotyrosine as described in Example 3. The treatments were: no addition (lane 1); 50 ng/ml NGF (lane 2, + NGF); 100  $\mu$ g/ml anti-LNGFR IgG (lane 3, REX IgG); 100 mg/ml RtrkA.EX IgG (lane 4, RTA IgG); 5 100  $\mu$ g/ml nonimmune IgG (lane 5, Rabbit IgG); 67  $\mu$ g/ml RtrkA.EX Fab (lane 6, RTA Fab). The arrows on the right indicate proteins which show increased tyrosine phosphorylation during the assay. Each of the PC12 cultures were treated for five minutes with 10 NGF, or various antibody preparations, and changes in cellular tyrosine phosphorylation determined as described above.

Significant changes in phosphorylation were detected in response to NGF and the RtrkA.EX 15 IgG preparation, and the RtrkA.EX IgG-induced pattern was indistinguishable from that found in response to NGF. In contrast, both control rabbit IgG and anti-LNGFR IgG were ineffective. Also, Fab fragments of the RtrkA.EX antibody had no effect.

20 To show that the RtrkA.EX IgG effects reflected activation of the trkA receptor, effects of NGF and various antibodies on trkA phosphorylation levels were examined. TrkA is a tyrosine kinase receptor which has been shown 25 previously to be tyrosine phosphorylated and activated upon binding of NGF (Kaplan, et al., 1991b; Klein, et al., 1991). Therefore, PC12 cultures were treated as above with NGF, or antibody preparations, and then immunoprecipitated the trkA 30 receptor from the corresponding lysates. The precipitates were analyzed by blotting with the anti-phosphotyrosine antibody.

RtrkA.EX IgG induces trkA autophosphorylation. PC12 cells were treated as 35 described above with: no addition (lane 1); 10 ng/ml NGF (lane 2); 200 mg/ml RtrkA.EX Fab (lane 3,

RTA Fab); 200, 67, 22, and 7  $\mu$ g/ml RtrkA.EX IgG (lanes 4-7, RTA IgG); and 200  $\mu$ g/ml rabbit IgG (lane 8, Control IgG). TrkA receptor was immunoprecipitated from 250  $\mu$ g of each lysate by the 5 addition of rtrkA.cyt IgG and protein A-sepharose. The precipitations were separated on a 7.5% SDS gel and tyrosine phosphorylation detected as discussed in Example 3.

The RtrkA.EX IgG preparation induced a 10 concentration-dependent increase in trkA tyrosine phosphorylation after five minutes, while the RtrkA.EX Fab preparation and control nonimmune IgG did not. A similar concentration of RtrkA.EX IgG was needed to promote maximal phosphorylation as is 15 required to inhibit completely  $^{125}$ I-NGF binding (shown in Figure 1A). In a related experiment, the effect of the RtrkA.EX IgG preparation was tested in parallel on the PC12 cell line and on the PC12nnr5 line, a derivative of PC12 cells which lacks 20 detectable expression of trkA mRNA or protein (Loeb, et al., 1991). RtrkA.EX IgG was able to induce cellular phosphorylation in PC12 cells, but not in PC12nnr5. Transfection of trkA into PC12nnr5 restored its responsiveness to the RtrkA.EX IgG.

25

Example 5: RtrkA.EX Fab inhibits and RtrkA.EX IgG stimulates survival of neonatal sympathetic neurons.

To determine the effects of the trkA 30 antibodies on long-term responses to NGF, a classic in vitro assay for NGF action was utilized: the NGF-dependent survival and process outgrowth of rat neonatal sympathetic neurons from the superior cervical ganglion. These cells are dependent on NGF 35 during this period *in vivo* and *in vitro*. The withdrawal of NGF leads to a lack of process

outgrowth and apoptotic cell death. Neonatal sympathetic neurons were isolated and then cultured in the presence of NGF, NGF plus control nonimmune Fab fragments, or NGF plus RtrkA.EX Fab fragments.

5           Neonatal rat sympathetic neurons were isolated from superior cervical ganglia of newborn rats as described (Hawrot, E. and Patterson, P. H., *Meth. Enzymol.*, 53, 574-584 (1979)). The ganglia were treated with 1 mg/ml collagenase/dispase in  
10 CMF-PBS (45 minutes at 37°C; Boehringer Mannheim Biochemicals), and washed with the same buffer. The ganglia were triturated to remove the neurons, and the isolated cells washed several additional times in CMF-PBS. The cells were cultured on a collagen  
15 I substrate in a defined medium (Leibowitz L-15/CO<sub>2</sub> medium containing 1x nonessential amino acids, 1 mg/ml bovine serum albumin and 0.35% methocel, penicillin, streptomycin, glucose, and imidazole as described (Hawrot and Patterson, 1979)).

20           In some of the RtrkA.EX IgG activation experiments, the medium contained in addition: stable vitamin mix, fresh vitamin mix (Hawrot and Patterson, 1979) and N1 supplement (Bottenstein, et al., *Exp. Cell Res.* 125:183-190 (1980)).  
25           Essentially identical results were obtained under either condition.

After 24 hours, the cultures were fixed with PBS containing 5% sucrose and 2.5% glutaraldehyde prior to photography and cell counts.

30           Neurons were considered to have survived if they appeared phase-bright and had extended processes greater than two cell diameters in length.

As had been seen in the tyrosine phosphorylation assays, the RtrkA.EX Fab fragments  
35           were able to inhibit the NGF responses of these

cells, as assayed by survival (Fig. 3) and neurite outgrowth.

Figure 3 shows that RtrkA.EX Fab fragments inhibit NGF-dependent survival of sympathetic neurons. Isolated neurons from neonatal rat superior cervical ganglia were cultured in the presence or absence of 1 ng/ml NGF and 500  $\mu$ g/ml nonimmune or RtrkA.EX Fab fragments as indicated. After 24 hours, the cultures were fixed and the number of process-bearing cells determined. The average and range from duplicate wells are shown.

Photomicrographs of sympathetic neurons cultured in the presence of (a) no addition; (b) NGF; (c) NGF + nonimmune Fab; (d) NGF + RtrkA.EX Fab were taken. NGF was added at 1 ng/ml, and the Fab fragments used at 500  $\mu$ g/ml. After 24 hours, the cultures were fixed and photographed.

When the effect of the bivalent RtrkA.EX IgG preparation was tested quantitatively in the sympathetic neuronal survival assay, the RtrkA.EX antibody caused a small but reproducible decrease in NGF-dependent viability, while the anti-LNGFR and nonimmune IgG preparations had no obvious effects (Figure 4). However, when NGF was omitted from the culture medium, the RtrkA.EX antibody had a strong survival promoting activity, yielding a maximal survival of about 60% of that obtained with NGF (Fig. 4) and promoted extensive process outgrowth.

Figure 4 shows that RtrkA.EX promotes survival of sympathetic neurons. Neonatal rat superior cervical ganglion neurons were cultured in combinations of NGF and IgG preparations as indicated. NGF was used at 50 ng/ml and the IgG preparations at 10 or 100  $\mu$ g/ml. After 24 hours, the cultures were fixed and the number of process-

bearing neurons counted. The data shown are the average and range of duplicate cultures.

5 Data was obtained from sympathetic neurons cultured in the presence of the following: (a) NGF; (b) NGF + normal rabbit IgG (Control IgG); (c) NGF + anti-LNGFR IgG (REX IgG); (d) NGF + RtrkA.EX IgG (RTA IgG); (e) no addition; (f) normal rabbit IgG; (g) anti-LNGFR IgG; and (h) RtrkA.EX IgG. The antibodies and NGF were added at 100  $\mu$ g/ml and 50 10 ng/ml, respectively. Cultures were incubated 24 hours prior to fixation.

Neither the control IgG nor the anti-LNGFR antibody alone had any *in vitro* survival activity. In addition, RtrkA.EX Fab fragments were unable to 15 support sympathetic neuron survival. The effects of RtrkA.EX IgG were also tested on cultures containing primed PC12 cells (PC12 cells which have been previously exposed to NGF for seven days, resulting in differentiation). The RtrkA.EX IgG showed a 20 clear ability to promote neurite outgrowth of these cells in the absence of NGF; approximately 60% as many cells extended neurites as responded in the presence of NGF.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: CLARY, Douglas O.  
WESKAMP, Gisela  
AUSTIN, LeeAnn R.  
REICHARDT, Louis F.

(ii) TITLE OF INVENTION: ANTIBODIES THAT MIMIC ACTIONS OF  
NEUROTROPHINS

(iii) NUMBER OF SEQUENCES: 6

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Townsend and Townsend Khourie and Crew  
(B) STREET: Steuart Street Tower, One Market Plaza  
(C) CITY: San Francisco  
(D) STATE: California  
(E) COUNTRY: US  
(F) ZIP: 94105-1493

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/162,597  
(B) FILING DATE: 03-DEC-1993  
(C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Weber, Ellen L.  
(B) REGISTRATION NUMBER: 32,762  
(C) REFERENCE/DOCKET NUMBER: 2307G-541

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (415) 543-9600  
(B) TELEFAX: (415) 543-5043

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Cys Ser Val Leu Asn Glu Thr Ser Phe Ile Phe Thr Gln Phe Leu Glu  
1 5 10 15  
Ser Ala Leu Thr Asn Glu Thr Met Arg His  
20 25

## (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Cys Ala Arg Leu Gln Ala Leu Ala Gln Ala Pro Pro Ser Tyr Leu Asp  
1 5 10 15  
Val Leu Gly

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGCCGAATTC GCCCGCGCA GAGAACCTGA CTGAGC

## (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGCCGAATTC ATGTGCTGTT AGTGTCAAGGG ATGGGG

## (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 40 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCGAATTCCA TGGCGCGAGG CCAGCGGCAC GGGCAGCTGG

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCGAATTCCA TGGCTATTAT TCGTCCTTCT TCTCCACTGG GTCTC

## WHAT IS CLAIMED IS:

1. A method for activating a *trk* receptor comprising exposing cells having the *trk* receptor to a 5 multivalent immunoglobulin which binds to the receptor and activates the receptor.

2. A method of claim 1 wherein the *trk* receptor is selected from the group consisting of *trkA*, 10 *trkB*, and *trkC*.

3. A method of claim 1 wherein the immunoglobulin induces at least one member of the group consisting of an increase in phosphorylation of the 15 receptor, an increase in phosphorylation of a protein substrate that is phosphorylated in response to activation of the receptor, and promotion of an effector function of receptor activation.

20 4. A method of claim 3 wherein the effector function is a member of the group consisting of promotion of neuronal survival, promotion of neuronal differentiation, and improved neuronal function.

25 5. A method of claim 1 wherein the immunoglobulin is bivalent.

6. A method of claim 1 wherein the immunoglobulin is a monoclonal antibody.

30 7. A method of therapy for a neurologic disorder associated with suboptimal activity of a *trk* receptor, said method comprising administering to a mammal having the disorder a therapeutically effective 35 amount of a multivalent immunoglobulin which activates the receptor.

8. A method of claim 7 wherein the trk receptor is selected from the group consisting of trkA, trkB, and trkC.

5 9. A method of claim 7 wherein the immunoglobulin induces an increase in phosphorylation of the receptor thereby activating the receptor.

10 10. A method of claim 7 further comprising the step of administering at least one of an additive and a diluent simultaneously with the immunoglobulin.

15 11. A method of claim 7 wherein the effective amount is from about 0.1  $\mu$ g to about 1 mg per kg body weight of the mammal.

12. A method of claim 7 wherein the administration is selected from the group consisting of intravenous, intramuscular, intraventricular, and 20 parenteral pump implant administration.

13. A method of claim 7 wherein the immunoglobulin is a bivalent monoclonal antibody.

25 14. A method of claim 7 wherein the disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, peripheral neuropathy, nervous system cancer, cerebral ischemia, nerve tissue ischemia and epilepsy.

30 15. A method of claim 14 wherein the nervous system cancer is selected from the group consisting of primitive neuroectodermal tumors, neuroblastomas, medulloblastomas, ganglioneuromas, Ewing's sarcoma, 35 gliomas, glioblastomas and astrocytomas.

16. A method for diagnosing a neurologic disorder associated by suboptimal activity of a *trk* receptor, said method comprising:

- (a) obtaining a nerve cellular sample;
- 5 (b) exposing the sample to a bivalent immunoglobulin which (1) binds to the receptor and (2) induces an increase in the phosphorylation of the receptor; and
- 10 (c) assaying the sample for (1) binding to the bivalent immunoglobulin and (2) increased phosphorylation.

17. A method of claim 16 wherein the nerve cellular sample is from the peripheral nervous system.

15

18. A method for determining whether cellular material has a *trk* receptor comprising:

- (a) exposing the cellular material to a bivalent immunoglobulin which (1) binds to the receptor and (2) induces an increase in phosphorylation of the receptor; and
- 20 (b) assaying the cellular material for (1) binding to the bivalent immunoglobulin and (2) increased phosphorylation.

25

19. A multivalent immunoglobulin which binds to a *trk* receptor and functions as an agonist to the receptor.

30

20. An immunoglobulin of claim 19 wherein the receptor is selected from the group consisting of *trkA*, *trkB*, and *trkC*.

35

21. A monovalent immunoglobulin which binds to a *trk* receptor and blocks activation of the receptor.

22. A method for blocking activation of a *trk* receptor comprising subjecting the receptor to a monovalent immunoglobulin that binds the receptor.

1/3

FIG. 1A





FIG. 1B



2/3




FIG. 2





FIG. 3

3/3

FIG. 4



SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/13708

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,231,001 (KAPLAN ET AL.) 27 JULY 1993, see entire document.	1-15, 19, 20
Y	Journal of Neurochemistry, Volume 59, Number 6, issued December 1992, B. Knusel et al., "K-252 compounds: modulators of neurotrophin signal transduction", pages 1987-1996, see entire document.	1-15, 19, 20
Y	Nature, Volume 350, issued 14 March 1991, D.R. Kaplan et al., "Tyrosine phosphorylation and tyrosine kinase activity of the <i>trk</i> proto-oncogene product induced by NGF", pages 158-160, see entire document.	1-15, 19, 20

<input checked="" type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
-------------------------------------	--	--------------------------	--------------------------

• Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"g"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
22 FEBRUARY 1995	27 FEB 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>Matthew Fager</i> Jacqueline Krikorian
Faxsimile No. (703) 305-3230	Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/13708

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Journal of Neuroscience Research, Volume 32, issued 1992, L.A. Hutton et al., "Expression of p75 <sup>NGFR</sup> TrkA and TrkB mRNA in Rat C6 Glioma and Type I Astrocyte Cultures", pages 375-383, see entire document.	7, 8, 14, 15
Y	Current Opinion in Neurology and Neurosurgery, Volume 6, issued 1993, H. Persson et al., "Role and expression of neurotrophins and the trk family of tyrosine kinase receptors in neural growth and rescue after injury", pages 11-18, see entire document.	4, 7-9, 14, 15
Y	Molecular and Cellular Biochemistry, Volume 110, issued 1992, P.A. Barker et al., "The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins", pages 1-14, see entire document.	1-15, 19, 20
Y	WO, A, 92/16559 (KAPLAN ET AL.) 01 October 1992, see entire document.	1-15, 19, 20

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US94/13708

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-15, 19, 20

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US94/13708

**A. CLASSIFICATION OF SUBJECT MATTER:**  
IPC (6):

A61K 39/395; C07K 16/28; C12N 1/38; G01N 33/53

**A. CLASSIFICATION OF SUBJECT MATTER:**  
US CL :

424/130.1, 143.1; 530/388.22; 435/7.21, 244

**B. FIELDS SEARCHED**

Minimum documentation searched  
Classification System: U.S.

424/130.1, 143.1; 530/388.22; 435/7.21, 244

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, Medline, CAS, BIOSIS, WPIDS  
Search terms: trk, phosphorylate, activate, antibody, immunoglobulin, receptor, nervous system

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-15, 19, and 20, drawn to a method of activating a trk receptor, a method of therapy comprising activating a trk receptor, and to an immunoglobulin agonist for a trk receptor.

Group II, claims 16-18, drawn to a method of diagnosing a neurologic disorder and to a method of determining the presence of a trk receptor.

Group III, claims 21 and 22, drawn to a monovalent antagonist of a trk receptor, and to a method of blocking activation of a trk receptor.

The inventions listed as Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons. Groups I and III are different because the product and methods of Group I activate a trk receptor, whereas the product and method of Group III block the activation of a trk receptor. Groups I and III are different from Group II because the method of Group II relates to determining the presence of a trk receptor, and not to modulating the activity of a trk receptor. Note that PCT Rule 13 does not provide for multiple methods within a single application.

Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.